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ABSTRACT
The use of cardiovascular risk scores remains the foundation for risk stratification to
guide clinical management. Clinicians have access to several cardiovascular risk scores in
practice settings. While having several risk scores with different risk factors may provide more
information, it does not imply accuracy of the cardiovascular risk score used to calculate
individual patient cardiovascular risk. The objective of this study was to compare the
Framingham Risk score, Reynolds Risk scores, and the Pooled Cohort Risk Equation (3
commonly used equations) scores with respect to ability to predict cardiovascular events in a
diverse ethnic population. Additionally, the potential predictive utility of three novel risk factors
(carotid intima media thickness, peripheral arterial tonometry and vasa vasorum) was examined
in relation to ability to improve 10-year cardiovascular risk prediction.
A secondary analysis of the longitudinal prospective study cohort known as Heart
Strategies Concentrating On Risk Evaluation (Heart SCORE) was conducted. The
cardiovascular risk scores of study participants who did and did not experience a cardiovascular
event composite index consisting of myocardial infarction, death, stroke, acute ischemic stroke,
or revascularization were assessed using methods of calibration and discrimination overall and
by race and gender. When examining performance of the 3 risk scores, the overall 10-year
absolute predicted cardiovascular risk varied substantially (e.g. approximately 2-fold) and this
wide variation in predicted 10-year cardiovascular risk was present across race and gender.
Nonetheless, despite the wide variation in estimates of absolute risk, the 3 cardiovascular risk
score equations were strongly associated with future cardiovascular risk overall and by race and
xi

gender. There was some indication that the Reynolds risk score was the most accurate measure
of future cardiovascular risk. The 3 novel risk factors examined did not significantly improve 10year cardiovascular risk prediction above and beyond the standard demographic and clinical
variables used in these well-known equations.

xii

CHAPTER 1: INTRODUCTION
Background
Cardiovascular Disease
The overall rate of death attributable to cardiovascular disease was 222.9 people per
100,000 Americans in 2013 (Mozaffarian et al., 2015). Coronary heart disease causes
every 7 deaths in the United States (Mozaffarian et al., 2015). By 2030, cardiovascular disease
(CVD) will account for 32.5% of all deaths; with coronary heart disease estimated to be the
primary cause of death in 14.9% of males and 13.1% in females (Gaziano & Gaziano, 2012).
Governance and policy documents recommend the use of multivariate risk assessment scores to
identify high-risk individuals, as well as to identify novel risk factors for coronary heart disease
and cardiovascular disease (Brindle, Beswick, Fahey, & Ebrahim, 2006; Siontis, et al., 2012,
Goff et al., 2013; Mozaffarian et al., 2015).
Heart disease terminology includes coronary heart disease (CHD), coronary artery
disease (CAD), cardiovascular disease (CVD), and most recently, atherosclerotic cardiovascular
disease (ASCVD). Coronary heart disease (CHD), also referred to as coronary artery disease
(CAD), is the narrowing of the small blood vessels that supply blood and oxygen to the heart
(United States National Library of Medicine, 2016). Cardiovascular disease (CVD) encompasses
a group of major disorders of the heart and the arterial circulation supplying the heart, brain and
peripheral tissues. Cardiovascular disease includes all diseases of the circulatory system,
coronary heart disease, cerebrovascular disease, hypertension, peripheral arterial disease,
1

rheumatic heart disease, congenital disease, heart failure, deep vein thrombosis and pulmonary
embolism (Go et al., 2014; Goff et al., 2013). Atherosclerotic cardiovascular disease (ASCVD)
includes coronary heart disease (CHD), stroke, and peripheral arterial disease, all of presumed
atherosclerotic origin (Stone et al., 2014). Atherosclerotic cardiovascular disease (ASCVD),
coronary heart disease (CHD), and cardiovascular disease (CVD) are not interchangeable terms.
The Framingham Heart Study risk scores and the Reynolds Risk Scores for men and
women are established multivariate risk assessment scores designed to predict the absolute risk
(as a percentage) for coronary heart disease or cardiovascular disease events over a specified
period of time (usually 10 years). In the 2013, the American College of Cardiology/American
Heart Association guidelines recommended a new multivariate risk assessment score called the
Pooled Cohort Equations Risk Score (Goff et al., 2013). The terminology used in the
development of cardiac risk assessment scores is purposeful and distinct from one another. The
Pooled Cohort Equations Risk Score assesses the risk of experiencing an initial atherosclerotic
cardiovascular disease (ASCVD) event (opposed to coronary heart disease or cardiovascular
disease event). Coronary death, nonfatal myocardial infarction or CHD death, fatal or nonfatal
stroke are considered an ASCVD event (Goff et al., 2013). Of note, all of these well-established
risk scores use many of the same variables, such as age and blood pressure, yet with different
weighting criteria.
In 1948, little was known about cardiovascular heart disease, which was the leading
cause of death in the United States (Framingham Heart Study, 2016). The Framingham Heart
Study began under the direction of the United States National Health Institute to identity
common risk factors or characteristics contributing to heart disease. The cardiovascular risk
factors identified from the previous fifty years of this research are classified as non-modifiable or
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modifiable risk factors. Non-modifiable risk factors include age, gender, family history, and
having had a previous heart attack. Modifiable risk factors are hypertension (HTN),
hyperlipidemia, diabetes mellitus (DM), and smoking (Framingham Heart Study, 2016).
Currently, as a society, we have failed to modify largely preventable (modifiable) risk factors
and the crisis of cardiovascular risk and disease prevalence exists due to deficient management
of modifiable risk factors (Wachira & Stys, 2013).
Racial disparities in cardiovascular risk. The increase in burden of cardiovascular
disease risk factors and the deficient management of cardiovascular risk factors in minorities is
well established (Go et al, 2014; Mozzaffarian et al., 2015). In the previous fifty years of
cardiovascular research, minorities have been poorly represented within the study populations
(Goff et al, 2013). To address this known disparity, the American College of
Cardiology/American Heart Association 2013 guidelines emphasize the need for cardiovascular
disease risk assessment and intervention research to include minorities in their study populations
to address and alleviate their undeserved cardiovascular risk burden. According to 2012
estimates from the National Health Interview Survey, 6.3% of blacks, 5.4% of Hispanics or
Latinos, and 21.0% of Asians have coronary heart disease. Among American Indians or Alaska
Natives, 8.2% have heart disease (Mozzaffarian et al., 2015). Non-Hispanic black males and
females have the highest overall death rate attributed to cardiovascular disease compared to nonHispanic white males and females, as well as Hispanic males and females (Mozaffarian et al.,
2015). Blacks in the United States endure the highest prevalence (44%) of high blood pressure in
the world (Go et al, 2014). The prevalence and treatment of high blood pressure in minorities
continues to challenge the health care community. Blacks develop high blood pressure earlier in
life and have 1.5 times greater death rate of death attributable to heart disease than do whites.
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While there have been great strides to increase awareness of high blood pressure among blacks,
the odds of controlling blood pressure among blacks is 27% lower than it is in whites, and blood
pressure of Mexican American males and females are the least controlled of all subgroups (Go et
al., 2014). Blacks, Mexican Americans, and Hispanics/Latinos also bear a disproportional burden
of the cardiovascular disease risk factor of diabetes mellitus in the United States (Go et al.,
2014). Diabetes diagnosed by a physician in adults is more prevalent in black men (13.5) and
Mexican American men (11.4) compared to white men. There is also an increased prevalence of
diabetes in black females and Mexican American females compared to white women (Go et al.,
2014).
Cardiovascular Risk Scores
Physicians use the cardiovascular risk factors (non-modifiable and modifiable) to identify
patients who will benefit from primary prevention therapies, and most importantly, to deliver
preventative care for asymptomatic individuals and for those identified as at risk for
cardiovascular disease (Anderson et al., 2013; Brindle, Beswick, Fahey, & Ebrahim, 2006;
Siontis et al., 2012). With the use of these scores, an individual’s cardiovascular risk factors are
entered into a multivariate equation, which quantifies their estimated risk for both fatal and nonfatal cardiac events. When referring to cardiovascular risk, the term “risk” can mean the cause or
probability of an unwanted event (e.g. myocardial infarction), or the expected value of the
probability of an unwanted event multiplied by a measure of event severity, (e.g. the probability
of myocardial infarction and the associated probability of death) (Payne, 2012).
Generally, an individuals’ cardiovascular risk is considered over a fixed, finite period of
time, most commonly over 10 years (Payne, 2012). A 20% probability of risk for developing
cardiovascular disease over a finite period of time is considered high risk, intermediate risk is 10-
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20%, and low risk is considered less than 10% risk (Kones, 2011). These risk categories are not
derived empirically, nonetheless, are accepted and widely utilized throughout the medical
community. The utility for calculating cardiovascular risk from various multivariate equations,
such as the Framingham Risk Score, is to identify high-risk patients and provide information for
clinical decision-making (Barroso et al., 2010).
Framingham risk score. The Framingham Risk Scores were created as part of the
Framingham Heart Study, and they are among the most thoroughly validated and widely used
predictive scores in the medical literature (Tzoulaki, Liberopoulous, & Ioannidis, 2009). The
Framingham risk score(s) were developed during the peak incidence of cardiovascular disease in
the United States (Mendes, 2010; Payne, 2012), with the intention of prospective risk assessment
for coronary heart disease (CHD) in both men and women without overt CHD (Tzoulaki, et al.,
2009). Initially, the Framingham Heart Study developed a multivariate equation to predict
individual risk of developing of coronary heart disease (Wilson, Casetelli, & Kannel, 1987). A
modified version of this multivariate equation is used to predict the 10-year risk for coronary
heart disease using the known constituent risk factors (age, blood pressure, total cholesterol or
low density lipoprotein (LDL) level, high density lipoprotein (HDL) level, smoking status, and
the presence of diabetes mellitus) (D’Agostino et al., 2001). These risk factors (modifiable and
non-modifiable) are used in the multivariate equation to derive Framingham Risk, and are also
referred to as traditional risk factors. As the research focus evolved from prediction of coronary
heart disease risk to prediction of cardiovascular disease risk, D’Agostino et al. (2008) published
a 10-year Framingham Risk Score (FRS) for cardiovascular disease assessment. However, a
well-known limitation of the Framingham Risk Scores is that primarily male white cohorts were
used to develop and assess the performance of the Framingham models. The extent to which the
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scores would generally to future risk of women and other races and ethnicities was not initially
considered.
Reynolds risk score. As described above, a significant potential limitation of the
development and validation of model performance of the Framingham Risk Scores for coronary
heart disease and cardiovascular disease is the use of primarily male white cohorts. To address
this gender disparity in cardiovascular risk assessment, Ridker, Buring, Rifal, and Cook (2007)
developed a cardiovascular risk score specifically for women called the Reynolds Risk Score.
The Reynolds Risk Score is a multivariate equation that includes the same cardiovascular risk
factors used in the Framingham Risk Score, but importantly, includes a family history of
cardiovascular disease, which is not used in the calculation of the Framingham Risk Score. The
inclusion of lifestyle factors, and family history of cardiovascular disease as well as markers of
preclinical disease (high sensitivity C-reactive protein) is recommended to guide clinical
decisions regarding preventative therapy in women (Mosca, Barrett-Connor, & Wenger, 2011).
Pooled cohort risk equations. In 2008, the National Heart, Lung, and Blood Institute
(NHLBI) in a collaboration with the American College of Cardiology (ACC) and American
Heart Association (AHA) sought to develop updated clinical practice guidelines to assess
cardiovascular risk, reduction of risk through lifestyle modification, management of cholesterol,
as well as overweight/obesity management by 2014 (Stone et al., 2014). Work groups appointed
by the National Heart Lung and Blood Institute updated guidelines on blood cholesterol, blood
pressure and overweight/obesity. Expert panels were tasked with providing current evidence
based foundation for treating cholesterol, as well as primary and secondary prevention of
Atherosclerotic Cardiovascular Disease (ASCVD) in men and women. Expert panels reviewed
data from randomized control trials, systematic reviews, and meta-analyses on treating blood
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cholesterol, blood pressure, obesity, and ASCVD. Their findings were conveyed in The 2013
American College of Cardiology/ American Heart Association/ The Obesity Society/ Guidelines
for the Management of Overweight and Obesity in Adults (Jensen et al., 2014), and The 2013
American College of Cardiology/ American Heart Association Guidelines on the Treatment of
Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (Stone et al., 2014).
The Work Group was tasked with charging the separate expert panels to update
guidelines on cholesterol, blood pressure, and overweight/obesity with the optimal clinical
cardiac risk assessment model (Goff et al., 2013). A review of risk assessment methodology for
cardiovascular risk scores was conducted for the purpose of recommending a clinical risk
assessment for clinical practice to the work groups. The Work Group found that existing risk
score research used non-representative populations or data with limited ethnic diversity,
narrowly defined endpoints, endpoints influenced by provider preferences (e.g.
revascularization), and endpoints with poor reliability (e.g. angina and heart failure) (Goff et al.,
2013). Furthermore, the Framingham Risk Score recommended by previous guidelines, was not
based on contemporary data, and was dominated by a white population with limited coverage of
other ethnic groups, and had an insufficient focus on ischemic stroke (Preis & Kristensen, 2015).
Therefore, using a current United States population, the Work Group developed a
cardiovascular risk assessment equation called the Pooled Cohort Risk Score Equation. The
Pooled Cohort Risk Equation is the clinical risk assessment score recommended in the
2013ACC/AHA Guidelines on the Assessment of Cardiovascular Risk (Goff et al., 2013). These
current guidelines specify the current cardiovascular research aims of investigating the use of
traditional and non-traditional (novel) cardiovascular risk factors in risk assessment research
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with the inclusion of minorities in study populations to address the known racial disparities (Goff
et al., 2013).
Novel Cardiovascular Risk Factors
Extensive epidemiological, pathological, and basic science data indicate that the
development of atherosclerosis, the precursor of atherosclerotic cardiovascular disease
(ASCVD), occurs over decades and is related to long-term and cumulative exposure to causal,
modifiable risk factors (Goff et al., 2013). The American College of Cardiology (ACC) and
American Heart Association (AHA) advocate for the inclusion of non-traditional (novel) risk
factors to assess cardiovascular risk assessment. Novel risk/non-traditional risk factors were
included in the rigorous review of clinical research by the expert panels charged with updating
the ACC/AHA Guidelines. The Work Group assessments of the novel risk factors of family
history of premature cardiovascular disease, high sensitivity C-reactive protein, coronary artery
calcium (CAC), and arterial brachial index (ABI) indicate promise for clinical utility among the
novel risk markers, based on limited data (Goff et al., 2013). The improvement of existing
cardiovascular risk factors as well as the innovation of improving cardiovascular risk estimation
is reliant on the search for new cardiovascular risk factors beyond the traditional four major risk
factors of hypertension, hypercholesterolemia, diabetes mellitus an smoking (Goff et al.,). This
pursuit is apparent by the inclusion of the non-traditional/novel risk factors of inflammatory
marker high sensitivity C-reactive protein by Ridker et al., (2007), subclinical atherosclerosis
measures of coronary artery calcium (CAC) scores by Lakoski et al., (2007), genetic risk scoring
by Morrison et al, (2007) in cardiovascular risk scores and cardiac risk research. Whereas there
are many novel risk factors that could be examined, three potentially promising novel risk factors
are described below and form the basis for some of the analyses conducted in this research.
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Carotid intima media thickness. The innermost layer of the arterial wall is the intima
and consists of a single layer of endothelial cells coming into direct contact with blood. The
media layer is mainly smooth muscle and provides the majority of thickness of the arterial wall.
The adventitia is the outer most layer and is composed of primarily collagen (Naik, Gamad, &
Bansod, 2013). Atherosclerosis is responsible for the thickening of the arterial wall. The intima
media thickness is a validated measure to evaluate atherosclerosis presence in the arterial wall,
particularly in carotid artery. The increase of intima media thickness threatens a brain infarction
or cardiac attack (Naik et al., 2013).
Using high-resolution ultrasound imaging, the assessment of carotid intima media
thickness is a validated assessment tool for the detection of atherosclerosis (Nair, Malik, &
Khatter, 2012; Naik, et al., 2013). Importantly, carotid intima media thickness (CIMT) correlates
with traditional risk factors and coronary atherosclerosis severity (Nair et al., 2012). Carotid
intima media thickness was used as an endpoint in the Multi-Ethnic Study of Atherosclerosis
(MESA) (Folsom et al., 2008), the Atherosclerosis Risk Communities Study (Chambless et al.,
1997; Chambless, et al., 2000), and Framingham Offspring Study (Polak et al., 2011) as a marker
of atherosclerosis. Importantly, findings indicated an association of carotid intima media
thickness with coronary heart disease and stroke making carotid intima media thickness a
potentially useful independent predictor of cardiovascular disease.
Pulse amplitude tonometry. It is suggested that dysfunction of the endothelial layer of
blood vessels is participatory in the pathogenesis of atherosclerosis (Briasoulis et al., 2012). Loss
of utility from endothelial dysfunction plays a role in anti-atherogenic effects and all stages of
atherosclerosis including plaque formation rupture. There are data showing that the endothelial
dysfunction in coronary arteries is analogous to endothelial dysfunction in vascular peripheral
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arteries (Briasoulis et al., 2012). Initial diagnostic tests to measure endothelial function were
invasive and timely. Pulse amplitude tonometry (PAT) is a non-invasive diagnostic test of
endothelial function by measuring pulse amplitude with a fingertip plethysmogrophy to sense the
changes in blood volume of a digit with each arterial pulsation (Briasoulis et al.,). The inclusion
of PAT in multivariate risk assessments offers potential promise in understanding the role
endothelial dysfunction in cardiovascular risk assessment.
Vasa vasorum. Endothelial dysfunction is the first step in the development of
atherosclerosis (Mortiz et al., 2012). In the walls of larger arteries, progressive inflammatory
disease results in atherosclerosis lesions. The role of the vasa vasorum (in the adventitia of large
arteries) is a central tenant of atherosclerosis development (Mortiz et al., 2012). The vasa
vasorum (VV), or ‘the vessels of the vessels’, deliver nutrients and oxygen to arterial walls and
removes waste produced by cells in the wall or introduced by diffusional transport through the
endothelium of the artery (Ritman & Lerman, 2007). In the presence of disease, thickening of the
intima wall inhibits oxygen diffusion (Moreno, Purushothaman, Sirol, Levy, & Fuster, 2006),
and causes media thinning and necrosis (Baikoussis et al., 2011).
The neovascularization (formation of vasa vasorum ‘vessels of the vessels’) seems to be
closely associated with carotid plaque progression and lesion vulnerability. Atherosclerotic
plaque rupture is the critical, final event leading to unstable angina and myocardial infarction
(Baikoussis et al., 2011). Research has shown an association between the increase of vessel-wall
(vasa vasorum) as well as plaque micro vessels and ruptured atherosclerotic plaques (Baikoussis
et al., 2011). Thus, there is reason to pursue the detection of the presence of vasa vasorum in the
vascular wall and in the atherosclerotic lesions in early atherosclerosis (Mortiz et al., 2012).
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Statement of the Problem
Death attributable to cardiovascular disease remains the number one killer of men and
women in the United States (Mozaffarian et al., 2015). The burden of disease is high (Go et al.,
2014) with the consequences of this preventable epidemic including individual mortality and
morbidity, family suffering and staggering economic costs (Gaziano & Gaziano, 2012). The head
to head comparisons of emerging cardiovascular risk models are important to perform so as to
identify and document the improvements in cardiovascular risk prediction (Go et al., 2014; Goff
et al, 2013; Siontis et al., 2012). A research study to compare the predictions of 10-year
cardiovascular disease risk using the Framingham Risk Score, the Reynolds Risk Score for
Women, the Reynolds Risk Score for Men, as well as the Pooled Cohort Risk Equations
comparing predicted cardiovascular risk by race and gender has not been previously conducted
and published. The Pooled Cohort Risk Equations application to an ethnically diverse population
addresses the known research gap to assess both short and long term atherosclerotic
cardiovascular disease (ASCVD) risk with outcomes in all race/ethnic groups, and across age
spectrums and in women and men (Goff et al., 2013).
Statement of the Purpose
The purpose of this research study was to assess and compare the Framingham Risk
score, Reynolds Risk score, and the Pooled Cohort Risk Equations score with respect to ability to
predict cardiovascular events in a diverse ethnic population.
Study Aims
The specific aims of this study were:
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1. Examine the overall predictive utility of the Framingham cardiovascular risk score,
Reynolds Risk Score for women, Reynolds Risk Score for Men and the Pooled
Cohort Risk Equations using methods of calibration and discrimination.
2. Examine the overall predictive utility by race of the Framingham cardiovascular risk
score, Reynolds Risk Score for women, Reynolds Risk Score for Men and the Pooled
Cohort Risk Equations using methods of calibration and discrimination.
3. Assess the predictive utility of the Framingham cardiovascular risk score, Reynolds
Risk Score for women, Reynolds Risk Score for Men and the Pooled Cohort Risk
Equations with the inclusion of the variables (novel risk factors) carotid intima media
thickness (CIMT), pulse amplitude tonometry (PAT), and/or vasa vasorum (VV).
Study Implications
The results of this study may provide additional knowledge for cardiovascular disease
risk assessment and management. In particular, by examining 3 different risk scores in the same
study population, and with separate consideration or race and gender, finding may shed insight as
to which score may be most appropriate for certain individuals. These findings can be compared
with current guidelines promulgated by the American College of Cardiology/American Heart
Association to estimate risk and predict cardiovascular events. Furthermore, the effects on risk
prediction with the inclusion of the variables carotid intima media thickness (CIMT), pulse
amplitude tonometry (PAT), and vasa vasorum (VV) will permit assessment of their predictive
value and clinical utility in cardiovascular risk assessment.
Definition of Terms
The following terms are defined and used throughout this research.

12

Atherosclerotic Cardiovascular Disease - coronary heart disease (CHD), stroke, and
peripheral arterial disease, all of presumed atherosclerotic origin (Stone et al., 2014).
Atherosclerotic Cardiovascular Disease Event-an initial ASCVD event of a nonfatal
myocardial infarction or CHD death, fatal or nonfatal stroke, over a ten year time period among
people free of ASCVD at the initiation of the time period (Goff et al., 2014).
Cardiovascular Disease- includes all diseases of the circulatory system and prevalence of
cardiovascular disease includes individuals with hypertension, heart disease, stroke, peripheral
artery disease, and diseases of the veins.
Coronary Heart Disease- includes acute myocardial infarction, other acute ischemic
(coronary) heart disease, angina pectoris, atherosclerotic cardiovascular disease, and all other
forms of chronic ischemic coronary heart disease (Go et al., 2014)
Mortality-The total number of deaths attributable to a given disease in a population
during a specific interval of time, usually 1 year, reported. These data are compiled from death
certificates and sent by state health agencies to the NCHS (Go et al., 2014).
Morbidity—Incidence and prevalence rates are both measures of morbidity (e.g.,
measures of various effects of disease on a population) (Go et al., 2014).
Myocardial Infarction- a heart attack occurs when flow of oxygen rich blood is suddenly
blocked from going to a section of the heart. If blood flow is not restored quickly the section of
the heart, the muscle begins to die. National Heart, Lung, and Blood Institute, 2016).
Coronary heart disease risk factors- conditions or habits that raise ones’ risk of coronary
heart disease (CHD) and heart attack. These risk factors also increase the chance that existing
CHD will worsen (National Heart, Lung and Blood Institute, 2011).
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CHAPTER 2: LITERATURE REVIEW
Introduction
This literature review examines the established cardiovascular disease risk factors of race,
age, lipids (low density lipoprotein, triglycerides, high density lipoprotein) physical inactivity,
obesity, hypertension, diabetes, the metabolic syndrome, smoking, and a family history of
cardiovascular disease (CVD). The novel cardiovascular risk factors C-reactive protein (hsCRP), carotid intima media thickness (CIMT), pulse amplitude tonometry (PAT) and vasa
vasorum (VV) are also reviewed. The Framingham Heart Risk Score (2008), Reynolds Risk
Score for women (2007), Reynolds Risk Score for men (2008), and Pooled Cohort Risk
Equations Score (2013) used to predict 10-year cardiovascular risk are reviewed. In addition, the
methods of calibration and discrimination used to evaluate cardiovascular risk score models are
reviewed.
A series of searches in CINAHL, Pubmed, and Ovid Medline were conducted to support
the aims of this research from August 2013 until January 2016. Searches were refined for the
search terms cardiovascular risk, cardiovascular risk factors, and cardiovascular risk models. The
search terms of Framingham risk equation, Reynolds Risk Score, and American Heart
Association guidelines where used as well. Additionally, a search was performed for each of
cardiovascular risk factors used for this research.
Throughout Chapter 2, when reporting the percentage of individuals in the population
with the cardiovascular risk factors of high lipids, DM, and obesity, the American Heart
Association used data from the 2007-2010 National Health and Nutrition Examination Survey
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[NHANES]. NHANES surveys to assess the health and nutritional status of adults and children
in the United States through both participant interviews and physical examinations. The
prevalence of cigarette smoking and physical inactivity data were reported using the National
Health Interview Survey [NHIS].
Cardiovascular Risk Factors
Race. The racial disparity of a higher burden of cardiovascular disease risk factors in
minorities is well known. Specifically, there is known racial disparity of cardiovascular risk
factors of diabetes mellitus, hypertension, high triglycerides, and low high-density lipoprotein
among Blacks, Mexican Americans, and Hispanic/Latinos. According to the American Heart
Association, black males have the highest prevalence of cardiovascular disease followed by
Whites, then Mexican American men. This prevalence pattern is also seen among Black, White,
and Mexican American women (Goff et al., 2013). Interestingly there appears to be a lower
prevalence of high low-density lipoprotein (LDL) and triglycerides among blacks compared to
other cardiovascular disease risk factors such as physical inactivity, hypertension and diabetes
mellitus. The American College of Cardiology/American Heart Association 2013 guidelines
highlight the need for cardiovascular disease risk assessment and intervention research to include
minorities in their study populations to address and alleviate their undeserved cardiovascular
disease risk burden.
Age. Aging is associated with significant structural and functional changes in skeletal
muscle (Garcia & Goldenthal, 2008b). After the fourth decade of life, the decline of muscle mass
and muscle quality is paralleled by the decline in both muscle strength and maximal oxygen
uptake (Garcia & Goldenthal, 2008a). These changes decrease total energy expenditure and
physical activity that then increase the prevalence of obesity, particularly abdominal obesity.
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These physiological changes contribute to the prevalence of insulin resistance, hyperlipidemia
and hypertension in individuals over the age of forty. Insulin resistance increases with age
independent of total adiposity changes (Garcia & Goldenthal, 2008a). Insulin resistance and
obesity accelerate aging due to the oxidative stress and inflammation resulting in a shorter life
span. Increased fat mass, particularly visceral adiposity, increased circulation of inflammatory
proteins and the increased cellular accumulation of triglycerides that result from aging may
predispose individuals to insulin resistance. However, in men and women in their eighth and
ninth decades of life, triglycerides, total cholesterol, and LDL-C tend to be lower (Garcia &
Goldenthal, 2008a).
Independently, cardiovascular risk is influenced by age, but is not necessarily an invariant
risk factor and is highly dependent on the presence of other risk factors (Kannel & Vasan, 2009).
Cumulative exposure of anthropogenic risk factors occurs with aging (National Cholesterol
Education Program (NCEP) Expert Panel on Detection, 2002). Cardiovascular remodeling
results from the long-term burden of cardiovascular risk factors (Kannel & Vasan, 2009). Results
of the Framingham Heart Study data indicated that non-smoking 50-year olds who were not
diabetic, with total cholesterol less than 180 mg/dl, and blood pressure less than 120/80 mmHg
had a 5% to 8% risk of developing cardiovascular disease (Lloyd-Jones et al., 2006). Individuals
of the same age with two or more risk factors had a 50% to 68% lifetime risk (Lloyd-Jones et al.,
2006). Kannel and Vasan (2009) presented the notion of age itself as a risk factor as contrasted
with the long term exposures to risk factors over time. However, the complexity and
individuality of the aging process lend itself to variations in cardiovascular risk acquisition.
Therefore, age is imperative to include in multivariate cardiovascular risk models, but is
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intertwined with other cardiovascular risk factors such as triglycerides, low-density lipoprotein
(LDL), and diabetes (Kannel & Vasan, 2009).
Lipids. Low-density cholesterol (LDL) comprises sixty to seventy percent of the total
serum cholesterol and is the major anthropogenic lipoprotein (Grundy et al., 2004). Cholesterol
is a fat-like substance (lipid) that travels in the blood within lipoproteins, of which contain both
lipid and proteins (NCEP, 2002). The current ACC/AHA guidelines recommend untreated total
cholesterol of <200mg/dL for cardiovascular health and to reduce CVD and stroke risk (Go et
al., 2014). Currently, it is estimated that 31.9 million (13.8%) adults have serum cholesterol

Low density lipoprotein. Low-density lipoprotein is the primary target of cholesterollowering therapy (NCEP, 2002). According to the Adult Treatment Panel III, a LDL cholesterol
level of 130 to 159mg/dL is classified as borderline high, 160 to 189 mg/dL is considered high;
an LDL of 190mg/dL and above is considered very high. Data from the NHANES 2007-2010
indicated adults had a mean LDL cholesterol level of 115.8mg/dL. The reported LDL levels for
non-Hispanic white men (115.1 mg/dl) and women (115.7 mg/dL), non-Hispanic black men
(115.9 mg/dL) and women (114.2mg/dL), and Mexican American men (119.7mg/dL) and
women (115.0mg/dL) indicated less racial disparity compared to other cardiovascular disease
risk factors, such as hypertension and diabetes mellitus.
Triglycerides. A fasting triglyceride level of 150mg/dL and above is considered high and
a risk factor for cardiovascular disease and stroke (Go et al., 2014). Adult triglyceride levels
according to the NHANES 2007-2010 averaged 130.3 mg/dL. Overall, men had a higher mean
level of triglycerides (141.7 mg/dL) compared to women (119.1 mg/dL). Mexican American
men (161.4 mg/dL) and women (134.1 mg/dl) had the highest mean triglycerides compared to
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non-Hispanic white men (140.0 mg/dL), non-Hispanic white women (121.5 mg/dL) and nonHispanic black men (111.3 mg/dL) and non-Hispanic black women (94.4mg/dL)(Go et al.,
2014).
High density lipoprotein. High-density lipoprotein comprises twenty to thirty percent of
the total serum cholesterol (NCEP, 2002). A HDL cholesterol level of <40mg/dL in adult males
and <50 mg/dL in adult females is considered to be a risk factor for heart disease and stroke. The
NHANES 2007-2010 data indicated a mean HDL level of 52.5mg/dL as well as greater racial
and gender variation in HDL levels compared to LDL levels. High density lipoprotein levels
were as follows: non-Hispanic white men (46.7 mg/dl) and women (58.1 mg/dL); non-Hispanic
black men (52.6 mg/dL) and women (58.7mg/dL), and Mexican American men (45.4mg/dL) and
women (53.7mg/dL) (Go et al., 2014). The triad of high triglycerides, high LDL-C and low highdensity lipoprotein cholesterol (HDL), is strongly associated with type 2 diabetes and the
metabolic syndrome (Payne, 2012.) Disappointingly, combining statins with additional
medications targeting lipid abnormalities has lacked efficacy and hyperlipidemia continues to
plague the at risk population (Payne, 2012).
Lipids and aging. In both men and women, total cholesterol increases with age and peaks
in the fifth decade for men and in the sixth decade for women (Kolovou, Marvaki, & Bilianou,
2011). Both aging and menopause are posited to cause an unfavorable lipid profile that increases
cardiovascular risk (Kolovou & Bilianou, 2008). Compared to premenopausal women,
postmenopausal women have higher total cholesterol, low-density lipoprotein, and triglycerides
and lower high-density lipoprotein. As men age, androgens negatively influence their lipid
profile in conjunction with the increased accumulation of abdominal fat associated with aging.
Importantly, the presence of central obesity correlates with low HDL and high triglycerides
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(Kolovou et al., 2011). Kolovou et al., (2011) propose the ideal lipid profile for healthy aging
that consists of a lipid panel typical of low risk for atherosclerotic disease, such as found in
centenarians, as well as the protective factors of no smoking, body mass index (BMI) below
25kg/m2, proper lifestyle, and a set of ‘longevity’ genes. Centenarians possess a lipid profile
(high HDL, low LDL) indicative of low risk of atherosclerotic disease and research has yet to
determine the role of genetic factors in these individuals that possess “familial” longevity
(Kolovou, Kolovou, Vasiliadas, Wierzbicki, & Mikhilidis, 2011). Longevity is defined as
survival to the age of 90 and older and has been observed to cluster within families (Murabito,
Yuan, & Lunetta, 2012). Lower levels of cardiovascular risk factors in middle life or early years
predict survival and health up to 85 years of age. Yet the interaction between genes, modifiable
behaviors, and environmental factors on longevity is unknown (Murabito et al., 2012).
Physical inactivity. Physical inactivity remains a major risk factor the development of
cardiovascular disease and diabetes mellitus type 2 (Anderson et al., 2013). The current
ACC/AHA guidelines indicate that 150 minutes a week of moderatemin/week of vigorous activity) are needed to achieve cardiovascular health (Go et al., 2014). As
of 2010, only 41.5% of adults met this criteria. According to 2014 National Health Interview
Survey data, women were less active than men and inactivity increased with age (Mozaffarian et

al., 2015). Non-Hispanic black and Hispanic adults were more likely to be inactive compared to
non-Hispanic white adults (Mozaffarian et al., 2015).
Adherence to the recommended CVD risk factor guidelines has been associated with a
27% lower mortality in those individuals without chronic conditions (diabetes mellitus, cancer,
myocardial infarction, angina, cardiovascular disease, stroke, or respiratory disease) and for
individuals with chronic comorbidities mortality was reduced by up to 46% (Schoenborn &
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Stommel, 2011). Physical activity has been reported to reduce low-density lipoprotein (LDL) and
triglyceride levels, raise high-density lipoprotein (HDL) cholesterol, improve insulin sensitivity,
and lower blood pressure (NCEP, 2002).
Obesity. Obesity is a well-known risk factor for the development of the cardiovascular
disease risk factors of HTN, dyslipidemia, DM and the Metabolic Syndrome (Fox et al., 2014;
Mozaffarian et al., 2015). The health risks imposed by obesity may also be mediated by
hypertension, diabetes mellitus, and lipid profile imbalances (Gaizano & Gaizano, 2012; NCEP,
2002). A complete cardiovascular disease risk assessment includes measures for being
overweight, obesity and for central adiposity. Central adiposity (abdominal fat) is considered to
be more atherogenic compared to total body fat (Everson-Rose et al., 2009). Obesity is defined
as a body mass index (BMI) of at least 30 kilograms/m2.
Currently, 68% of US adults are overweight or obese and 35% of US adults (13 million
individuals) are considered to be obese (Go et al., 2014). Mexican American men (36%) and
women (45%) as well as non-Hispanic black men (38%) and women (54%) were more likely to
be overweight or obese than non-Hispanic white men (34%) and women (33%) (Go et al., 2014).
Additionally, data from the Multi-Ethnic Study of Atherosclerosis (MESA) study concluded a
larger proportion of white, black and Hispanic participants were overweight (60-85%) or obese
(30%-50%) compared to Chinese American participants who were overweight (33%) or obese
(5%) (Burke et al., 2008). Obesity remains an epidemic that plagues the United States. While
obesity is more prevalent among Mexican American and non-Hispanic black men and women,
its impact on cardiovascular risk is prevalent in all races and ethnicities.
Hypertension. High blood pressure (hypertension) is a prevalent and most importantly is
a preventable risk factor for cardiovascular disease and stroke (James et al., 2014). High blood
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Hg, or a diastolic blood pressure
High blood pressure
causes extensive force of the blood against arterial walls which creates microscopic tears in the
artery walls, which then results in scar tissue and accelerates the arterial wall hardening process
that occurs with aging (American Heart Association, 2012). It is not surprising that seven of ten
individuals who experience their first heart attack, and eight out of ten individuals who
experience their first stroke, have high blood pressure (Go et al., 2014).
Hypertension (HTN) is a major independent risk factor for CHD. Regrettably, the
treatment of HTN is unable to fully diminish the coronary heart disease risk it causes (Grundy et
al., 2004). According to current estimates, 78 million (33%) adults in the United States who are
20 years of age or older have high blood pressure (Go et al., 2014). Hypertension is more
prevalent in men 45 years and younger compared to women. However, women are about as
likely as men to develop high blood pressure during their lifetimes (Go et al., 2014; Mozaffarian

et al., 2015) Of those individuals with hypertension, individuals 60 years and older have the
highest prevalence of HTN (66.7%) (Go et al., 2014). However, high blood pressure affects more
women that are 65 years and older compared to men of the same age category (Go et al., 2014;
Mosca, Barrett-Connor, & Wengeret, 2011).
The prevalence and treatment of high blood pressure in minorities continues to challenge
the health care community. In the United States, hypertension is most prevalent among nonHispanic black males (43.0%) and females (45.7%), as well as white men (33.9%) and women
(31.3%)(Go et al., 2014). Mexican American men (27.8%) and women (28.9%), represent the
ethnicity with the least controlled blood pressure, which in turn puts them at greater risk.
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African Americans have the highest prevalence (44%) of high blood pressure in the
world (Go et al., 2014; Mozaffarian et al., 2015). Blacks develop high blood pressure earlier in
life and have a 1.5 times greater rate of death attributable to heart disease compared to whites
(Center for Disease Control, 2014). While great strides have been made to increase awareness of
high blood pressure among blacks, the odds of controlling blood pressure among blacks is 27%
lower than it is in whites (Center for Disease Control, 2014). According to the National Health
and Nutritional Examination Survey (NHANES) 2007-2010, the blood pressure of Mexican
American males and females are the least controlled of all (Go et al. 2014).
Diabetes. According to the National Health and Nutritional Examination Survey
(NHANES) 2007- 2010 and 2012 statistics, currently 19.7 million people have physiciandiagnosed Type 2 diabetes mellitus (DM) and 56.5% of adults met the criteria for type 2 diabetes
mellitus (Mozaffarian et al., 2015). Of those 19.7 million, 6.8 million were not treated with
glucose lowering therapy. Among the 12.9 million adults on glucose lowering therapy, 7.8
million (60.5%) did not have their hyperglycemia controlled (Go et al., 2014). Blacks, Mexican
Americans, and Hispanic/Latino also bear a disproportional burden of the cardiovascular disease
risk factor of Diabetes Mellitus (DM) in the United States (Go et al., 2014). The risk of being
diagnosed with DM is disproportionality higher among Asian Americans (18%), Hispanic/Latino
(66%) and non-Hispanic blacks (77%) as compared to whites (Mozaffarian et al., 2015).
The increased incidence of diabetes mellitus (DM) has resulted in an increase in coronary
heart disease, stroke, and heart failure associated with diabetes (Go et al., 2014). Diabetics are
considered at a high risk for cardiovascular disease regardless of the presence of other factors
(NCEP, 2002; Payne, 2012). Additionally, diabetes is associated with at least a 60% increased
prevalence of elevated low density lipoprotein, hypertension, and obesity (Go et. al., 2014).
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Mortality among adults with diabetes is two to four times higher compared to non-diabetic
adults. With the stakes so high for individuals with diabetes, the outlook is ominous when 8.2
million U.S. adults remain undiagnosed by a physician with diabetes and 87.3 million adults are
considered pre-diabetic.
The metabolic syndrome. Cardiovascular risk prediction was propelled by the
introduction of the Metabolic Syndrome (MetS) in the late 1990’s. A consensus within the
medical community is that medical obesity, its medical complications, and the metabolic
syndrome, warrant greater attention. The National Health and Nutrition Examination Survey
(NHANES) III (1988-1994) affirmed that approximately 24% U.S. adults over the age of 20 had
the metabolic syndrome, a clustering of at least 3 of 5 CVD risk factors (Ford et al., 2004).
According to the NHANES 1999-2000 and the NHANES 2003-2006, the rates of metabolic
syndrome have continued to rise from 27% to 34%. Individuals with the metabolic syndrome are
twice at risk of developing cardiovascular disease in 5 to 10 years and have a five-fold increase
in risk for type 2 diabetes mellitus as compared to those individuals without metabolic syndrome
(Eckel, Alberti, Grundy, & Zimmet, 2010). The priority is the identification of patients with the
metabolic syndrome in the clinical arena, and to promote the reduction of lifestyle risk factors
(Alberti, Zimmet, & Shaw, 2006).
The term metabolic syndrome is the condition of the presence of risk factors of a
metabolic origin for cardiovascular disease and diabetes (Alberti et al., 2009). However, there
has been considerable disagreement in the medical community regarding the terminology and
diagnostic criteria of the metabolic syndrome over the last decade. The World Health
Organization (WHO) proposed a formal definition of metabolic syndrome in 1998. Insulin
resistance was emphasized as the major underlying risk factor. Insulin resistance was required
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for diagnosis of the metabolic syndrome. Individuals with type 2 diabetes were not excluded
from the diagnosis. Diagnosis was made on the basis of several markers of insulin resistance plus
two additional risk factors of either hypertension (blood pressure
-density lipid (HDL)
cholesterol <35 mg/dL in men and <39 mg/dL in women), central obesity (waist-to-hip ratio
>0.90 in men or >0.85 in women and/or body mass index (BMI) >30 kg/m2), or
min-to-creatinine ratio
et al., 2004).
Definitions of metabolic syndrome put forth by the International Diabetes Federation
(IDF) in 2005 and the ATP-III definitions that would follow in 2009, differed from the 1998
World Health Organization definition. Ethnic-specific criteria for waist circumference
measurement to emphasize the role of insulin resistance and central adiposity in the metabolic
syndrome was included in the definition of metabolic syndrome according to the International
Diabetes Federation (IDF) in 2005 (Wyne, 2005).
Assessment for metabolic syndrome includes the presence of central obesity (waist
circumference >94 cm for European men and >80 cm for European women, with ethnicityspecific values for other groups) plus two of the following factors are required to diagnose the
metabolic syndrome: elevated triglyceride level (> 150 mg/dL or undergoing specific treatment
for increased triglycerides), low HDL cholesterol (< 40 mg/dL in men and <50 mg/dL in women
or undergoing specific treatment for reduced HDL cholesterol), presence of hypertension
(systolic blood pressure >130 mm Hg or diastolic blood pressure > 85 mm Hg or undergoing
treatment for previously diagnosed hypertension), and elevated fasting plasma glucose (> 100
mg/dL or previously diagnosed type 2 diabetes) (Grundy et al., 2004). Ethnic-specific values for
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waist circumference have been established for the following groups: European, Sub-Saharan,

Chinese, Malay and Asian(Gaizano & Gaizano, 2012; Grundy et al., 2004; Wayne
2005).
In 2002, the Third Report of the National Cholesterol Education Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, published by the
American College of Cardiology/American Heart Association, concluded an individual can be
classified as having the metabolic syndrome if three or more of the following five criteria are
met: abdominal obesity (waist circumference >102 cm in men and >88 cm in women),

ing glucose
, 2004). The International Diabetes Federation has recognized that in
the United States, the Adult Treatment Panel (ATP)

The metabolic syndrome is not an absolute risk indicator for cardiovascular disease, but
rather encompasses the risk factors of a pro-inflammatory state (elevated high sensitivity Creactive protein), and other non-metabolic factors such as physical inactivity, advanced age, sex,
diet, cigarette smoking, and family history of premature coronary heart disease. These were
considered risk factors but were not specified in the definition of the metabolic syndrome
(Alberit et al., 2009; Grundy, et al., 2004,). Acquired underlying risk factors of metabolic
syndrome include obesity, weight gain, physical inactivity, and unhealthy diet (Carnethon et al.,
2004; Eckel et al., 2010).
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Smoking. The devastating effects of smoking on the body, in particular on the
cardiovascular system, are well known. Smoking is regarded as the most important preventable
risk factor for cardiovascular disease (Anderson et al., 2013) with cessation significantly
reducing the risk of coronary heart disease and cardiovascular disease morbidity and mortality
(National Cholesterol Evaluation Program, 2002; Go et al., 2014). Of the 5 million deaths caused
by tobacco, approximately 1.6 million are CVD related (Gaziano & Gaziano, 2012). Worldwide,
it is projected that 1.6 billion people will smoke cigarettes (Gaziano & Gaziano, 2012).
Approximately 20% of adults currently smoke with a greater prevalence in U.S men
(20.5%) compared to women (15.9%)(Go et al., 2014; Mosca et al., 2011). Overall mortality
among smokers in the United States is three times higher than non-smokers (Go et al., 2014).
Smoking is a cardiovascular risk factor to those who do not smoke due to exposure to second
hand smoke. According to the 2006 United States Surgeon General’s Report, the exposure to
second hand smoke at home or at work increases the risk of developing coronary heart disease by
25% to 30% (Go et al., 2014). Regardless of the measures taken to educate and raise awareness
of the morbidity and mortality associated with smoking cigarettes, it still remains a prevalent risk
factor for cardiovascular disease. According to the trajectory for 2030, the burden of disease
attributed to tobacco will be 10 million deaths annually (Gaizano & Gaizano, 2012).
Family history of cardiovascular disease. Family history of cardiovascular disease is a
risk factor for the presence of coronary heart disease, and may be used to identify younger
patients who may benefit from early intervention (Kones, 2011). Family history is considered
coronary heart disease in a first-degree relative (parent, sibling, or offspring) (NCEP, 2002).
Among adults in the United States 20 years and older, 12.6% reported a parent or sibling that had
a myocardial infarction or angina prior to the age of 50 (Go et al., 2014). A paternal history of
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premature heart attack doubles the risk of a heart attack in men and more than doubles the risk in
women (Mozaffarian et al., 2015). Sibling history of cardiovascular disease increases the odds of
cardiovascular disease in men and women by 45% (Mozaffarian et al., 2015).
Several cardiovascular risk models QRISK (Q Research Cardiovascular Risk Algorithm),
ASSIGN (Assessing Cardiovascular Risk to Scottish Intercollegiate Guidelines Network), and
the Reynolds Risk Score include a family history of cardiovascular disease as a risk factor.
Genetic markers discovered thus far have not provided additional benefit to cardiovascular risk
assessment beyond the incorporation of family history in multivariate risk models (Ranthe et al.,
2013).
Cardiovascular Risk Assessment
Terminology of heart disease has evolved over the last fifty years from CHD (coronary
heart disease) referring to diseases of the vessels supplying the heart, to cardiovascular disease
(CVD), which encompasses diseases arterial circulation supplying the heart, brain and peripheral
tissues. The more recent evolution has been to atherosclerotic cardiovascular disease (ASCVD)
that entails coronary heart disease (CHD), stroke, and peripheral arterial disease, all of presumed
atherosclerotic origin. Therefore, the requirements for cardiovascular risk assessment have
evolved as well. The recommended risk assessment focused on estimation of ASCVD
(Atherosclerotic Coronary Disease) events. ASCVD events were defined as the first occurrence
of non-fatal myocardial infarction or coronary heart disease death, or non-fatal and fatal stroke.
Therefore, cardiac risk assessment has expanded beyond the traditional risk factors (e.g.
hypertension, hypercholesterolemia, diabetes mellitus and smoking). Investigators included the
non-traditional/novel risk factors of the high sensitivity C-reactive protein (hs-CRP) (Ridker et
al., 2008), subclinical atherosclerosis measures of coronary artery calcium (CAC) scores
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(Lakoski et al., 2007), and genetic risk scoring (AIRC cohort, Morrison et al., 2007) to predict
cardiovascular risk. However, and perhaps to some surprise, the inclusion of novel risk factors
into multivariate cardiovascular risk equation has generally failed to show even a nominal level
of improvement in discrimination (C-statistic). In the Atherosclerosis Risk in Communities
cohort (Folsom et al., 2006), combinations of inclusion of 19 novel risk factors increased the Cstatistic by just 0.000 and 0.005, and several decreased the C-statistic slightly compared to the
traditional risk factors. The inclusion of brain natriuretic peptide levels plus microalbuminuria to
a traditional cardiovascular risk model increased the C-statistic from 0.76 to 0.77 (Wang et al.,
2006). The inclusion of high sensitivity C-reactive protein (hs-CRP) and a family history of
cardiac events to the traditional risk factors in cardiovascular multivariate risk produced a
minimal change in overall model discrimination (Lloyd-Jones et al., 2004). However, the
inclusion of coronary artery calcium (CAC) scores to the Framingham Risk Score increased the
C-statistic more substantially from 0.02 to 0.11 (Hong et al., 2004). When evaluating the
addition of novel risk factors, it is important to consider that most are correlated with traditional
risk factors and the ability to change the C-statistic substantially is difficult (Lloyd-Jones, 2010).
This research study considered the novel risk factors high sensitivity C-reactive protein,
carotid intima media thickness, Peripheral Arterial Tonometry, and Vasa Vasorum. These novel
risk factors are reviewed below.
High sensitivity C-reactive protein. High Sensitivity C-reactive protein (hs-CRP) is an
inflammatory biomarker primarily produced in the liver in response to the inflammatory
cytokine, interleukin-6, and is synthesized in adipose tissue, by arterial smooth muscle cells, and
by endothelial cells (Anderson et al., 2013). High sensitivity C-reactive protein is associated with
risk for both coronary artery disease (CAD) and stroke (Anderson et al., 2013). The Women’s
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Health Initiative study and the Physicians’ Health Study showed an association of hs-CRP and
cardiovascular disease events that were independent of other cardiovascular risk factors (Ridker,
Cushman, Stampfer, Tracy, & Hennekens, 1997; Ridker, Hennekens, Buring, & Rifai, 2000). In
the Women’s Health Initiative study, healthy women belonging to the highest quartile of hs-CRP
had an increased risk of cardiovascular disease events compared with those in the lowest
quartile. In the Physicians’ Health Study, baseline hs-CRP concentrations were significantly
higher among initially healthy men who had myocardial infarction or stroke compared to men
who did not. Concentrations of hs-CRP concentrations were also associated with future risk of
myocardial infarction and stroke when added to the model containing other cardiovascular risk
factors. More recently, Justification for the Use of Statins in Primary Prevention: an Intervention
Trial Evaluating Rosuvastatin (JUPITER) (Ridker et al., 2008) demonstrated that a high
sensitivity C-reactive protein level successfully identified a population with ‘‘hidden risk’’ for
cardiovascular disease and provided evidence for the potential utility of hs-CRP as an indicator
of therapy efficacy in CVD primary prevention.
According to Yousuf et al. (2013), the use of a single measurement of high sensitivity Creactive protein (hs-CRP) for risk assessment may misclassify individuals. Sources of hs-CRP
variations are body mass index, metabolic syndrome, diabetes mellitus, hypertension, oral
contraceptive use, physical exercise, moderate alcohol consumption, periodontal disease, dietary
patterns, environmental pollutant burden, and smoking, all of which can cause significant
baseline variation. Findings from a reexamination of the National Health and Nutritional
Examination Survey (NHANES) database indicated intra-individual variation among hs-CRP
measurements. Among individuals, a second discordant measurement of hs-CRP reclassified
32% of the individuals previously classified as having a high hs-CRP. There was additional
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empirical evidence of intra-individual variation, which resulted in overall risk reclassification in
the Multi-Ethnic Study of Atherosclerosis (MESA) trial. In the MESA follow up, 54% of
individuals had discordant hs-CRP levels and 69% of individuals with elevated baseline hs-CRP
were reclassified into a lower cardiovascular risk category after subsequent measurements
(Yousuf et al., 2013). Using a risk threshold of hs-CRP > 2mg, hs-CRP is advocated by some in
the medical community. However, more than 50% of all adults and 41% of 20-year-olds in the
United States have a hs-CRP levels >2 mg (deGoma et al., 2013).
Findings from the Dallas Heart Study and the Multi-Ethnic Study of Atherosclerosis
(MESA) trial indicate the lack of a direct association between high sensitivity C-reactive protein
and coronary atherosclerosis (Blaha et al., 2011; Gupta et al., 2012). Obesity is suggested as the
biological modifier between hs-CRP and coronary atherosclerosis. DeGoma, Dunbar, Jacoby, &
French (2013) reported hs-CRP was useful in the identification of patients classified as at high
risk according to the Framingham Risk Score. However, its use may need to be restricted to only
those patients identified as at intermediate or high risk for cardiovascular disease. However, the
reclassification of intermediate-risk patients with the addition of hs-CRP to existing Framingham
Risk Score variables may not meaningfully alter clinical management. Lastly, there is
inconclusive evidence that reducing high sensitivity C-reactive protein hs-levels prevents
coronary heart disease (deGoma et al., 2013).
Carotid intima media thickness. Carotid intima media thickness (CIMT) measures the
thickness of the intima and media walls of the carotid arteries intima, which are the largest
conduits of blood going to the brain (Go et al., 2014). Carotid intima media thickness is an
earlier manifestation of atherosclerosis than coronary artery calcium, because thickening
precedes the development of frank atherosclerotic plaque (Go et al., 2014). Carotid intima media
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thickness is a known risk factor for cardiovascular disease and has been shown to predict the risk
of stroke and coronary events (Bots, Hoes, Koudstaal, Hofman, & Grobbee, 1997; Chambless et
al., 2000; Lorenz, Markus, Bots, Rosvall & Sitzer, 2007; O’Leary et al., 1999). Risk assessment
among individuals at intermediate risk for cardiovascular disease is most likely to be improved
by means of carotid ultrasound measurements to determine carotid intima media thickness or
carotid plaque (Peters, Bakker, den Ruijter & Bots, 2012).
Men from the Kuopio Ischemic Heart Disease Risk Factor Study (Salonen & Salonen,
1991), free of vascular disease and aged 43–60 years at baseline (n=1257) were followed-for 3
years. Findings indicated men with a 0.1 mm increase in thickening of the carotid artery wall
were at an 11% increased risk of myocardial infarction (Salonen & Salonen, 1993). Moreover,
greater progression of carotid intima media thickness (CIMT) values over a 2-year period was
found in men with high low-density lipoprotein cholesterol levels (Salonen & Salonen, 1990). In
the Atherosclerosis Risk in Communities (ARIC) cohort (Folsom et al., 2006), the mean CIMT
measures were higher in men of all ages compared to women. However, the rate of intima media
thickness progression in the common carotid artery was 0.01 mm/year for men and women.
Carotid intima media thickening (CIMT) has been associated with smoking (Raitakari et
al. 2003; Howard, et al. 1994), and was significantly higher in patients with familial
hypercholesterolemia (Wittekoek et al., 1999). Additionally, findings from The Insulin
Resistance and Atherosclerosis study (Wagenknecht et al., 2003) indicated the CIMT of diabetic
patients without known coronary artery disease was similar to the CIMT of non-diabetics with
known coronary artery disease. Carotid intima media thickness progression has been found to be
significantly associated with age, race, systolic blood pressure, and diabetes (Ahuja et al., 2014).
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Of note, blacks have higher CIMT burden than whites (Mackinnon, Jerrard-Dunne, Porteous, &
Markus, 2010; Manolio, et al., 1995).
Ahuja et al. (2014) aimed to study the racial differences in carotid intima media thickness
progression over a four to six year period in 393 middle-aged men. The population-based sample
consisted of whites (n=199), blacks (n=39), and Japanese Americans (n=155) aged 40-49 years
who were not diabetic, hypertensive, or taking lipid-lowering medication and were free of
clinical cardiovascular disease at baseline. Carotid intima media thickness progression was the
highest in Japanese American compared to white and black men. Intima thickness progressed
faster in blacks compared to whites (Ahuja, et al., 2014).
Despite the association with smoking and high cholesterol, the inclusion of carotid intima
media thickness (CIMT) to traditional risk factors in multivariate cardiovascular risk prediction
models does not appear to improve risk prediction. Data from the Carotid Atherosclerosis
Progression Study (CAPS) found that when added to the Framingham Risk Score and Systematic
Coronary Risk Evaluation (SCORE) models, carotid intima media thickness did not significantly
improve risk prediction (Lorenz, Schaefer, Steinmetz, & Sitzer 2010). In a review by Simon
Megnien and Chironi (2010), only modest improvement to risk prediction occurred with the
addition of carotid intima media thickness despite its ability to independently predict coronary
heart disease (Robertson, Fowkes, & Price, 2012). In a rigorous review of twelve studies by
Peters, den Ruijten, Bots & Moons (2012); nine studies demonstrated an increase in
discrimination (C-statistic) when CIMT was added to the traditional risk assessment.
Importantly, there were various definitions for CIMT and cut-offs for intermediate
cardiovascular risk used across the 12 studies reviewed.
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According to the most recent American College of Cardiology/American Heart
Association guidelines, carotid intima media thickness (CIMT) is not recommended for routine
measurement in clinical practice for risk assessment for a first atherosclerotic cardiovascular
disease event. The Peters et al (2012) findings were not supported by the meta-analysis done by
Den Ruijter.et al. (2012) analysis of 14 cohorts consisting of 45,828 individuals during a median
follow up of 11 years (Go et al., 2014). During the follow up period 4,007 individuals
experienced either an initial myocardial infarction or stroke. The Framingham Risk Score (FRS)
and an extended FRS model with common CIMT measurements were used to estimate the
absolute 10-year risks to develop a first-time myocardial infarction or stroke. The discrimination
(C-statistic) of both models was similar C = 0.75, 95% CI [0.74 - 0.76] and 0.75, 95% CI, [0.750.76] respectively. However Den Ruijter et al. (2012) stated that the improvement in 10-year risk
to predict first-time myocardial infarction or stroke was not likely to be of clinical importance.
According to Nair, Malik and Khatter (2012), in the earlier studies measuring CIMT the
measurements were performed by visually detecting the leading edges of the blood intima,
media, and adventitia interfaces. This is in contrast to more recent studies that use a computer
based automated edge detection method. Therefore, among many of the large population based
studies the reported carotid IMT measurement, they may have included plaque thickness in the
derived mean (Nair et al., 2012).
The reviewed studies utilized the study outcomes for coronary heart disease events and
cardiovascular disease events, and not atherosclerotic cardiovascular disease events. The
American College of Cardiology and American Heart Association guidelines described
incongruent findings as evidence for their current recommendation regarding not to include
CIMT in risk assessment for an atherosclerotic cardiovascular event.
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Peripheral arterial tonometry. The dysfunction of endothelial cells from decreased
nitric oxide (NO) bioactivity is associated with vascular inflammation, vasoconstriction, and
thrombosis which contributes to the development of atherogenesis which then progresses to
cardiovascular disease (Hamburg & Vita, 2006; Rubenstein et al., 2010; Widlansky, Gokce,
Keaney, & Vita, 2003).
Therefore, the assessment of microcirculatory vasomotor function may afford the
identification of early coronary arthrosclerosis. Endothelial function in coronary arteries is
closely related to the endothelial function in peripheral arteries (Briasoulis, et al., 2012).
Measurement of peripheral vasodilator response using fingertip pulse amplitude tonometry
(PAT) as a measure for endothelial dysfunction has been correlated with cardiovascular risk
factors, coronary artery disease, cardiovascular hospitalization, cardiovascular death, death, and
myocardial infarction (Patvardhan, et al., 2011; Rubenstien et al., 2010). The non-invasive digital
amplitude tonometry-detected endothelial dysfunction measures correlate with the more invasive
measures (coronary and brachial artery) measures of endothelial dysfunction, which are known
predictors of cardiovascular disease events. (Bonetti al., 2004; Kuvin, et al., 2003; Naik, &
Khatter, 2012).
Assessment of vascular function with pulse amplitude tonometry (PAT) involves
measuring pulse amplitude in the fingertip at rest and following the induction of reactive
hyperemia. Hamburg et al. (2008) evaluated the vascular response in relation to baseline PAT,
and expressed the hyperemic response (called the PAT ratio) as the natural logarithm of the ratio
of post-inflation to baseline pulse amplitude in the hyperemic finger divided by the same ratio in
the contralateral finger that served as the study control. Pulse amplitude tonometry assessment of
arterial reactive hyperemia from the Framingham Third Generation Cohort participants (n =
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1957) with a mean age of 40.9 years and comprised of 49% women, was associated with
cardiovascular disease risk factors (Hamburg et al., 2008). The baseline pulse amplitude was
higher in men than in women. However, male gender, body mass index, total and high-density
cholesterol ratio, diabetes mellitus, smoking, and lipid-lowering treatment were all associated
with a lower a PAT.
Mulukutla et al. (2010) evaluated whether black race is independently associated with
arterial endothelial dysfunction with digital pulse amplitude response to forearm occlusioninduced hyperemia. Among the 1,377 subjects, of which 41% were black, 67% were female and
had a mean age of 58.5 years enrolled in the Heart Strategies Concentrating on Risk Evaluation
(Heart SCORE) study, the authors found that black race was independently associated with a
lower pulse amplitude tonometry (PAT) ratio. Subjects were assigned to low, intermediate, and
high Framingham risk strata. Within each Framingham risk strata, blacks consistently had
significantly lower PAT ratio than whites signifying greater endothelial dysfunction in blacks
(Mulukutla et al., 2010).
Pulse amplitude tonometry ratios of white and black races in the low Framingham risk
strata were higher (i.e. better endothelial function) when compared with individuals in the
intermediate or high-risk strata. Importantly, a lower PAT ratio in both races was associated with
a higher body mass index and cholesterol/high density lipoprotein ratio. These findings were
consisted with Hamburg et al. (2008), which further the postulate that race, gender, and
traditional cardiovascular risk factors are associated with PAT assessment of endothelial
dysfunction. Furthermore, PAT may be a useful measure of assessing overall risk for coronary
artery disease and may provide additional risk stratification to supplement the traditional
Framingham cardiovascular risk assessment.
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Peripheral arterial tonometry (stiffness) has been shown to be an important risk factor for
cardiovascular disease (Go et al., 2014). Coronary endothelial dysfunction evaluated by invasive
methods to predict coronary disease events and stroke (Lerman & Zither, 2005; Schachinger,
Britten & Zeiher, 2000; Suwaidi et al., 2000; Targonski et al., 2003) correlate with abnormal
non-invasive peripheral arterial tonometry results. However, current guidelines do not
recommend measuring peripheral arterial tonometry for cardiovascular risk in asymptomatic
adults. Endothelial function assessment is currently not standardized. This lack of
standardization remains a barrier to its use in risk assessment and in being recommended in the
current American College of Cardiology and American Heart Association guidelines (Go et al.,
2014).
Vasa vasorum. The inner most layer of the artery is the intima, the muscular middle
layer is the media and the adventitia is the outer most layer. The vasa vasorum (VV) or ‘the
vessels of the vessels’, form a network of micro vessels within the wall of the blood vessel in the
adventitia and infiltrate the outer media of vessel wall (Baukousis et al., 2011). In the absence of
disease, the vasa vasorum provide nutrition to the adventitia and the intima is fed oxygen by
diffusion from the lumen (Moreno et al., 2006). However the thickening of the intima wall with
disease progression inhibits oxygen diffusion (Moreno et al., 2006).
In the presence of hypoxia neovascularization, inflammation, and the activate angiogenic
factors occur (Pelisek, 2012). In atherosclerosis, the predominant form of neovascularization is
endothelial cell mediated angiogenesis (Manero et al., 2006). The resulting hyperplasia of the
adventitial vasa vasorum and intraplaque neovascularization is critical to plaque development
(Staib et al., 2010). Importantly, a hallmark of cardiovascular vulnerability is the
neovascularization of carotid plaque (Staib et al., 2013). Pelisek et al. (2012) found
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neovascularization to be closely associated with carotid plaque progression and lesion
vulnerability. Cardiac events leading to plaque rupture and clinical events appear to be consistent
with the plaque inflammation process (vascular leakage, inflammatory cell recruitment, and
intraplaque hemorrhage) (Staib, et al., 2010, 2013).
Contrast enhanced carotid ultrasound (CEUS) allows for noninvasive visualization of
vasa vasorum in the adventitial layer and of the vasa vasorum derived from intraplaque
neovascularization (Staib et al., 2013). This technique uses intravenous injection of
commercially available perflutren microspheres that serve as true intravascular tracers that can
be imaged in the carotid artery by real-time 2D ultrasonography. The imaging correlated strongly
with conventional angiography and magnetic resonance imaging studies (Staib et al. 2013). The
assessment of intraplaque neovascularization using CEUS correlated with the histological
examination results in animals and humans following a carotid endarterectomy (Coli et al., 2008;
Hoogi et al., 2011; Moguillansky et al., 2011). Currently, CEUS is used with great success, but
software to standardize intraplaque neovascularization quantitative assessments using CEUS is
still needed.
Contrast enhanced carotid ultrasound (CEUS) of the carotid artery has been shown to
accurately depict carotid stenosis of 70 % or more luminal narrowing and improve visualization
of wall irregularities including soft plaques, plaque ulcerations, and dissections (Staib et al.,
2013). Van den Oord et al. (2013) found the detection of atherosclerotic plaques using CEUS
(88%) compared to standard carotid ultrasound (77%) to be significantly higher. Based on these
findings, CEUS has an incremental value for the detection of subclinical atherosclerosis in the
carotid arteries. Cardiovascular disease risk estimation from a carotid intima media thickness
(CIMT) in combination with the presence of plaque in the carotid artery has been found to

37

significantly improve the prediction of cardiovascular events (Nambi et al., 2010). Vasa vasorum
assessment using CEUS is both non-invasive and novel. The full capacity of vasa vasorum
assessment to improve cardiovascular risk assessment is not currently known.
Cardiovascular Risk Scores
Cardiovascular risk scores permit the stratification of risk providing information to health
professions permitting the delivery of preventative services. Likewise, cardiovascular risk
estimation guides the selection of those who will receive more intensive disease preventative
intervention (Lloyd-Jones, 2010). Furthermore, the National Cholesterol Education Program
Adult Treatment Panel, the Seventh Joint Commission Committee on Prevention, Detection,
Evaluation and Treatment of High Blood Pressure (JNC-7) and U.S Preventative Services Task
Force (USPSTF), and the American Diabetes Association promote cardiovascular disease risk
assessment research to aid in the prevention of morbidity and mortality. However, there is no
ideal risk assessment equation or set of risk factors to identify high-risk and/or low-risk
individuals (Anderson et al., 2013).
A risk score distinguishes disease burden and severity, cost benefit, and facilitates the
effectiveness of disease prevention intervention (Lloyd-James, 2010). A risk score is derived
from a multivariate equation (algorithm) comprised of risk factors that are used to quantify
cardiac risk when preforming a risk assessment. To develop a multivariate risk equation the
cardiovascular risk factors used to predict risk for the selected cardiac event over a set time
period are predetermined. Likewise, the cardiac events cardiac heart disease (CHD) events,
cardiovascular disease (CVD) events, or atherosclerotic cardiovascular disease (ASCVD) events
are predetermined and are referred to as the risk study outcomes.
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The outcomes of risk assessment models are chosen to reflect disease prevention and
prevalence as well as the scientific statements and guidelines of medical research and science.
The evolution of cardiovascular disease guidelines and research findings is evident in in
cardiovascular risk outcomes. In 1998, the Framingham Risk Score outcomes were focused on
coronary heart disease and coronary artery disease (disease of arteries supplying the heart) events
of angina pectoris, unstable angina, myocardial infarction (MI), and coronary heart disease
(CHD) death. The inclusion of cardiovascular disease (major disorders of the heart and the
arterial circulation supplying the heart, brain and peripheral tissues) focused risk prediction by
using the risk study outcomes of stroke, stroke death, and cardiac failure in addition to
myocardial infarction, and coronary heart disease death. The Framingham Risk Score (2008) and
Reynolds Risk Score for women and men (2007, 2008) reflect the change in the state of the
science in risk prediction to a focus on cardiovascular disease opposed to coronary heart and
artery disease. Recently, the American College of Cardiology and American Heart Association
2013 guidelines recommended atherosclerotic cardiovascular disease (ASCVD) events to be
used as the risk assessment outcomes. An ASCVD event includes nonfatal myocardial infarction
or coronary heart disease, (CHD) death, or fatal or nonfatal stroke (Goff et al., 2014). Again, the
Pooled Risk Cohort Equations were created to assess the risk of ASCVD events; which reflect
the ongoing advancement of research in cardiovascular risk assessment. As risk factors that
measure disease and risk scores were developed, a statistical method to quantify the association
between risk factors and disease (represented by cardiovascular risk outcomes) was needed
(Lloyd-Jones, 2010).
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Cardiovascular Risk Model Evaluation
A cardiovascular disease risk model is capable of providing the risk of having the
specified cardiac events based on the presence or absence of cardiovascular risk factors. The
appropriate interpretation of 10-year risk of 10% is the following. Given 100 hundred similar
individuals, it is expected that 10 out of 100 will experience an event in the next ten years and
90% will not. In addition to obtaining absolute risk, the utility of a cardiac risk estimation model
includes the ability to discriminate future cases (presence of disease) from non-cases (absence of
disease), and the model provides information for the outcome of interest (Lloyd-James, 2010). A
formal statistical evaluation of model performance was needed with the epidemics of risk
prevalence, cardiovascular disease development with a subsequent observation of cardiovascular
events (Lloyd-Jones, 2010). Discrimination and calibration are the most widely used statistical
evaluation methods for cardiovascular disease risk models.
Discrimination. The ability of the model to rank order individual risk is assessed using
the Harrell’s C-index (C-statistic) and is the most widely reported measure of cardiovascular
disease risk model discrimination. Discrimination provides assessment of whether a risk
prediction model accurately rank orders individuals (e.g., are individuals with higher predicted
risk more likely to have events (Muntner et al., 2014). A risk model with perfect discrimination
would produce two non-overlapping sets of risk predicted probabilities, one for the probability of
an event and the other for non-events.
A C-statistic indicates the probability that a randomly selected individual who develops
the disease (case) will have a higher risk score compared to a randomly selected individual who
did not develop a disease (non-case) (Lloyd-Jones, 2010). The C-statistic ranges from 0.5
indicating that a score applied to the risk model is no better than random chance, to a 1.0 that
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indicates perfect discrimination. A C-statistic of less than 0.70 in a risk model indicates the
model provides less than adequate discrimination; a C-statistic between .70 and .80 is considered
acceptable. C-statistics between 0.80 to 0.90 are considered to provide excellent discrimination.
The use of the C-statistic as the sole measure to assess risk model discrimination has been
criticized since the rank comparison of cases and non-cases does not quantify the difference in
estimated risk between selected cases and non-cases.
Calibration. Calibration provides an assessment of whether a risk prediction model
accurately estimates the observed risk level (Muntner, et al. 2014). Calibration quantifies the
closeness of the predicted probabilities of an event to the observed event rates. The most widely
reported measure of model calibration for cardiovascular disease risk models is the Hosmer2

test. In order to assess a model’s calibration, the population is divided into

quartiles or related levels (e.g. quintiles, deciles) in order to visually assess the predicted risk
versus the observed event rate for each quartile. A Hosmer-

2

value of greater than 20

or a p-value of less than .05 indicates poor calibration for that cardiovascular disease risk model
(Muntner et al, 2014). Importantly a risk model can have discriminatory ability with poor
calibration. This would mean that the risk model was not an accurate predictor of future risk of
CVD at different levels of risk.
The Framingham Heart Score
The Framingham Heart Study is still considered to be groundbreaking research since its
inception in 1948 and continues to date with new generations of cohorts. It was a remarkable
advance in the understanding of the complexities of cardiovascular disease (CVD) etiology, risk
assessment, and the primary prevention of cardiovascular morbidity and mortality (Kones, 2011).
The traditional risk factors identified in the Framingham Heart Study remain central to
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cardiovascular risk assessment sixty years later. Since the earlier publications of the multivariate
Framingham risk equations, several models have been adapted to estimate “cardiovascular age,
vascular age, and cardiovascular age risk” (Anderson, Wilson, Odell, & Kannel, 1991; Anderson
et al, 2013; Brittain, 1982; Kannel, McGee, & Gordon, 1976; Levy, Wilson, Anderson &
Castelli, 1990; Wilson et al., 1987, 1988).
The Framingham Risk Score developed by Wilson et al. (1998) predicted the risk of the
development of coronary heart disease (CHD) not cardiovascular disease (CVD). To enhance the
utility of the Framingham Risk Score D’Agostino et al., 2008 developed a 10-year cardiac risk
score with cardiovascular disease outcomes of myocardial infarction, coronary heart disease
death, stroke, death from stroke, cardiac failure. The sample consisted of Framingham heart
study participants (n =8,491) included women (n=4,522) and men (n=3,969) ages 30 through 74
all being initially free of cardiovascular disease. Participants were followed over a 12-year period
for the development of coronary artery disease, stroke, peripheral artery disease (PAD), and heart
failure (HF). A sex-specific general cardiovascular risk function was also generated to estimate
10-year CVD risk and the ability of the risk prediction model to discriminate individuals who
experienced a CVD event from those who did not. Discrimination was evaluated using an overall
C-statistic. The sex-specific cardiovascular functions performed well, the C-statistics for the risk
function ranged from 0.763, 95% CI, [0.74 to 0.78] in men to 0.79, [0.77 to 0.81] in women. This
highly regarded research provided a 10-year general cardiovascular risk algorithm that is well
known and used throughout the world. The limitations of this research are the predominately
white male sample that has been continuously used in Framingham Risk Score research. Risk
factors of abdominal obesity, electrocardiogram evidence of left ventricular hypertrophy,
indications of insulin resistance, triglycerides, and a strong family history of premature
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cardiovascular disease are not included. However, D’Agostino et al. (2008) emphasize their
importance in the assessment of cardiovascular risk. An important limitation for all risk
assessment research identified by the authors is that risk scores, per se, do not translate to better
patient outcomes.
Issues with Framingham scoring. Previous research indicates that with recalibration,
the Framingham Risk scores can be tailored for use in non-Framingham populations (Marrugat et
al., 2003, 2007; Taylor et al., 2008). The Framingham Risk Score has been criticized for its
application to research populations with the under-representation of specific populations, a lack
of ethnic diversity, and over-estimating risk (Payne, 2012). Additionally, this risk score has been
criticized for under-representation of patients with diabetes and stages III and IV of kidney
disease (Payne, 2012). Furthermore, the Framingham Risk Score was found to under predict risk
in patients with stages III and IV of kidney disease (Chang & Kramer, 2011).
An overestimation of risk leads to overtreatment and underestimation of risk leads to
under treatment (deGoma et al., 2013). The Framingham Risk Score was developed using a
primarily male population, yet was subsequently deemed to be applicable to both men and
women. Findings from Framingham Risk Score research indicated under prediction of women’s
cardiovascular risk. According to research by Kones (2011), among women who sustained their
first myocardial infarction, 95% had Framingham Risk Scores in the low risk category, with the
remaining 5% in the intermediate category.
The Framingham Risk Score (FRS) preforms optimally (discrimination and calibration)
in white and black populations in the United States. In Asian American, American Indian,
Hispanic Americans, and Native Chinese populations, this method has only an acceptable
evidence of discrimination and overestimates cardiovascular risk (D’Agostino et al., 2001; Liu et
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al., 2004). The FRS has been found to overestimated risk by 50% in Non-White populations and
therefore is less applicable in many non-western populations (Mendis, 2010). Moreover, in some
European regions considered as low-risk populations, the Framingham Risk Score may
overestimate risk (Kones, 2011).
Reynolds Risk Score
Cardiovascular disease (CVD) remains the leading cause of death among women in the
United States (Go et al., 2014). The risk of acquiring cardiovascular disease increases after age
40. Women free of CVD at age 40 have a greater than 50% lifetime risk for developing CVD,
while women free of CVD at age 50 continue to have a high lifetime risk of 39.2% (Roger et al.,
2011) The premise that women should be treated the same as men in their prevention and
interventions for cardiovascular disease was challenged during the assembly of numerous
organizations in 2004 including the American Heart Association to sponsor the female specific
guidelines “Evidence Based Guidelines for Cardiovascular Disease Prevention in Women”
(Mosca et al., 2011b). To address the known gender disparity in cardiac risk assessment, Ridker,
Buring, Rifal, and Cook (2007) developed a cardiovascular risk score specifically for women
called the Reynolds Risk Score.
The Women’s Health Initiative study (Ridker et al., 2005) a nationwide cohort of U.S.
women free of cardiovascular disease and cancer at study entry was initiated in September 1992,
was used to develop the RRS for women. A prediction model was creating using development
(n=16,400) and validation (n=8,158) cohorts of women ages 45 and older who were followed for
a median a time period of 10.2 years. The cardiovascular events over the 10 years of 24,553
women ages 45 and older were used. The predicted risk model (developing Reynolds Risk
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Score) was compared to the Adult Treatment Panel III risk score model and Framingham Risk
Score using the events of the 24,553 women.
Discrimination was evaluated with Harrell’s C-index, and model calibration was assessed
2

with the Hosmer-

. The RRS (C = .80) demonstrated superior discrimination

compared to the ATP III 2001 score (C = .78), and the FRS (C = .75). Model calibration of the
2

2

=

2

<

<.001). The resulting

model known as the Reynolds Risk Score includes the risk factors of age, systolic blood
pressure, high-sensitivity C-reactive protein, total cholesterol, high density lipoprotein
cholesterol, hemoglobin A1C, diabetes status, smoking status and the presence of family history
of premature myocardial. Variables used in the 3 risk score of interest are listed in Table 1.
(Ridker et al., 2007).
Table 1. Risk Factors used in the Framingham Risk Score, Reynolds Risks Scores and Pooled
Risk Equation Risk Scores
Risk score
Age
Sex
TC
HDL
LDL
SBP
BP Rx
DM
Smoking
Hs-Crp
FH

FRS

RRS(W)

RRS (M)

Pooled

×
×
×
×

×

×

×
×

×
×

×
×
×
×

×
×
×
×

×

×

×
×

×
×
×

×
×
×

×

Note. FRS= Framingham Risk Score; RRS (W) = Reynolds Risk Score for Women; RRS (M) = Reynolds Risk
Score for Men; Pooled= Pooled Cohort Risk Equation; TC = Total Cholesterol; HDL = High Density Lipoprotein;
LDL = Low Density Lipoprotein; SBP = Systolic Blood Pressure; BP Rx = Blood Pressure Prescriptions
Medication; DM = Diabetes Mellitus; Hs-Crp = High Sensitivity C-reactive protein; FH = Family History.

Reynolds risk score for men. Based on the superior performance of the Reynolds Risk
Score (RRS) for women, Ridker, Paynter, Rifai, Gaziano, and Cook et al. (2008) aimed to use
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the same risk factors to develop a risk score for men. The RRS for men was developed using
participants (n=10,724) from the Physicians Health Study II (Christen, Gaziano, & Hennekens,
2000), a nationwide cohort of U.S. men 50 years and older free of cardiovascular disease,
diabetes mellitus, and cancer. A total of 1,294 cardiovascular events occurred (1,072 were
classified as incident coronary heart disease events of coronary revascularization or fatal or
nonfatal myocardial infarction) over the median follow up period of 10.8 years.
A traditional risk model based on age, blood pressure, smoking status, total cholesterol,
and high-density lipoprotien was compared to the Reynolds Risk Score model risk factors (age,
blood pressure, smoking status, total cholesterol, and high-density lipoprotein cholesterol, highsensitivity C-reactive protein and parental history of myocardial infarction before age 60). Risk
prediction of the traditional model and the RRS both utilize cardiovascular disease outcomes.
Additional analysis comparing the performance of the RRS form men to the ATP-III global risk
assessment (which incorporates the treatment of hypertension) using coronary heart disease as
the model outcome was conducted. The authors also compared the ATP-III risk model and the
RRS using a subgroup of study participants not taking lipid-lowering therapy at baseline.
Discrimination was evaluated with Harrell’s C-index, and model calibration was assessed
with the Hosmer-

2

. Calibration was computed with risk at 7 years since the majority

of participants had follow up completed through this time. Findings from the primary analysis
indicated the traditional risk factor model (HosmerScore (RRS) for men (Hosmer-

2

2

= 11.3) and Reynolds Risk

= 12.9) demonstrated similar levels of calibration.

For both the cardiovascular disease (CVD) and coronary heart disease (CHD) endpoints, the
Reynolds Risk Score had a better model fit (p < 0.001). The C-statistic of the traditional model
for cardiovascular disease (C = 0.69) and coronary heart disease (C = 0.68) was compared to the
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Reynolds Risk Score for men C-statistic for the cardiovascular disease endpoint (C = 0.70) and
the coronary heart disease endpoint (C = 0.70). This comparison indicated that the Reynolds Risk
Score improved discrimination. Model fit and C-statistics were superior in models that included
hs-Crp and parental history of myocardial infarction from the analysis of the cohort limited to
men not taking lipid-lowering therapy at baseline, and with the end point of coronary heart
disease. Despite these findings, the Reynolds Risk Score for men is rarely used. The Reynolds
Risk Score for women is more widely accepted and used within the medical community.
Reynolds risk score and the Framingham risk score. Cook et al., (2012) directly
compared three (Framingham Risk Score, Reynolds Risk Score for women, and the Adult
Treatment Panel III Risk Score) cardiovascular disease risk scores using a multi-ethnic case
cohort sample from the Women’s Health Initiative (WHI) Study observational cohort. A sample
of 1,722 women with major cardiovascular disease, as well as a random sub cohort of 1,994
women without prior cardiovascular disease, were assigned a Reynolds Risk Score, Framingham
Risk Score and Adult Treatment Panel III Risk Score. To foster an ethnically diverse sample,
black (n=200), Hispanic (n=53), and Asian (n=55) women and women with other/unknown
ethnicity (n=55) with major cardiovascular disease were included.
The risk study outcomes used in WHI data were coronary heart disease (CHD) events,
which consisted of myocardial infarction, coronary death, ischemic stroke, and cardiovascular
disease death. The Adult Treatment Panel III risk score is used to predict the same CHD events.
The Framingham Risk Score predicts cardiovascular disease risk (myocardial infarction,
coronary death, coronary insufficiency, and angina), cerebrovascular events (including ischemic
stroke, hemorrhagic stroke, and transient ischemic attack), peripheral artery disease (intermittent
claudication), and heart failure. While the Reynolds Risk Score also predicts cardiovascular
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disease risk, it is defined as incident myocardial infarction, ischemic stroke, coronary
revascularization, and cardiovascular death. The cardiovascular events experienced by the 1,722
individuals included 752 myocardial infarctions, 754 ischemic strokes, and 216 cardiovascular
disease deaths.
2

Instead of reporting the Hosmer-

statistic, calibration plots were used. The

study sample was divided into deciles of risk, and the predicted risk according to the Adult
Treatment Panel III risk score (ATP-III) was compared with observed 10-year rates of coronary
heart disease among only non-diabetics (since the ATP –III is intended for non-diabetic
individuals). According to the calibration plots, the ATP-III model overestimated risk of
coronary heart disease, but demonstrated better calibration of the risk of major cardiovascular
disease for women. Both the ATP-III model for coronary heart disease and the Framingham Risk
Score for cardiovascular disease (CVD) overestimated risk in black and white women.
Importantly, the poor calibration of the Framingham Risk Score may be due to it being
developed for the broader study outcome of total cardiovascular disease, including several other
conditions, namely angina, coronary insufficiency, transient ischemic attack, peripheral artery
disease, and congestive heart failure (Cook et al., 2012).
The C-statistics of the Adult Treatment Panel III risk score model (C = .75), Reynolds
Risk Score model (C = .76), and the Framingham Risk Score (C = .75) were similar. The
Reynolds Risk Score demonstrated statistically significant improvement in discrimination in all
women (p = .03) compared to the ATP-III model and the Framingham Risk Score model (p <
0.0001). Reynolds Risk Score discrimination was statistically significant among white (p <0001)
and black (p = .01) women, as compared to Framingham Risk Score model discrimination (Cook
et al., 2012).
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Using the National Health and Nutritional Examination Survey (NHANES) data sets
from 1999–2000 and 2001–2002, Tattersall, Ganon, Karmali, & Keevil (2012) examined the
cardiovascular risk of a representative U.S. population with the Reynolds Risk Score and the
Framingham Risk Score. Prior to the publication of the update lipids guidelines, Tattersall et al.,
(2012) examined two cardiovascular risk scores and the current lipid classification in a
representative population. The study population was intended to represent 53.6 million eligible
U.S. adults. In order to equate the population used to develop the Reynolds Risk Score (Ridker et
al., 2007, 2008), 1440 women ages 45-79 and 1,062 men ages 50-79 free of coronary heart
disease and diabetes mellitus were included in the representative population. Cardiovascular risk
categories of low, moderate, moderate-high, and high-risk categories risk values were defined
and were consistent with guidelines. Additionally, the number of adults with the representative
population who reached their low-density lipoprotein (LDL) goal was also assessed. The LDL
goals listed for each risk category were derived using the optional clinical goals of the U.S. lipid
guidelines (Grundy, et al., 2004). Low risk was indicated by a cardiovascular risk score less than
6% and LDL cholesterol <160 mg/dL; moderate-risk was indicated by a risk score between 6%
and 10% and LDL of <130 mg/dL; Moderate-high Risk was defined as a score between 10%
and, 20% and LDL < 100 mg/dL; and finally, high risk was indicated by a score of 20% and
LDL <70 mg/dL (Tattersall et al., 2012).
Findings indicated that use of the Reynolds Risk Score (RRS) assigned 13.9 % of women
and 9% of men to a higher risk category, while 37.5% of men and only 2% of women were
reclassified into a lower risk category. Using the RRS opposed to the Framingham Risk Score
(FRS), 10.5% of men and 0.6% of women met their low-density lipoprotein goal. According to
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these findings, the clinical management of 1.6 million women and 2.1 million men would change
using the Reynolds Risk Score, as opposed to the Framingham Risk Score.
Tattersall et al., (2012) noted the importance of the differing risk score outcomes, such as
those used for the Reynolds Risk Score and the Framingham Risk Score, for clinicians who may
seek to use these models as interchangeable. Models may be reported to be superior against
comparators when the examined outcome was the one that the model was developed for, but not
for one, which the comparator was developed (Siontis et al., 2012). Diverse endpoints of
myocardial infarction, stroke, coronary revascularization, and any cardiovascular death used for
the Reynolds Risk Score, compared to Framingham Risk Score endpoints of myocardial
infarction and fatal coronary heart disease, may limit comparison. It is known that differing
endpoints may impact risk classification, and consequently treatment decisions. Statistical
adjustments must be made to permit model comparison (Siontis et al., 2012).
Furthermore, the U.S. cohorts used to derive the Framingham Risk Score (FRS) and the
Reynolds Risk Score (RRS), as well as the populations of which these risk equations have been
applied, limits generalizability to other populations. Both the RRS and the FRS were developed
and validated in homogenous ethnicities within the U.S. and future studies of broader
populations across the U.S. that track event outcomes would allow better comparisons of the
calibration, discrimination and generalizability of these risk models (Tattersall et al., 2012).
The follow up period for the Women’s Health Initiative (WHI) used to develop the Reynolds
Risk Score (RRS) for women was 10.2 years (Tattersall, et al., 2012). In the Physicians Health
Study (PHS) II study used to develop the Reynolds Risk Score for men, the follow up period was
shorter at 7.2 years. The ethnically diverse population of women used to develop the RRS for
women allowed greater generalizability of results. However, the PHS II was not an ethnically
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diverse population, as it was comprised of U.S. male physicians at least 50 years of age with
relatively high socioeconomic status, excellent access to health care and information on
preventive therapies. Adjustment of risk estimates based on ethnicity are required to account for
different underlying rates of disease incidence, and prevalence of risk factors (Tattersall, et al.,
2012).
The use of cardiac risk scores is limited in certain areas of the world, and finding lowcost strategies for clinicians to obtain cardiac risk scores is essential (Berger, Jordan, LloydJones, & Blumenthal, 2010). The Framingham Risk Score and both Reynolds Risk Scores
contains some laboratory tests to estimate risk, and therefore, the risk of an individual cannot
easily be assessed without access to a laboratory. This may limit the use of the FRS and RRS,
particularly the Reynolds Risk Score requiring hs-CRP, to populations without laboratory access.
The Pooled Cohort Risk Equations
In 2008, the National Heart, Lung, and Blood Institute (NHLBI) in a collaboration with
the American College of Cardiology (ACC) and American Heart Association (AHA) sought to
develop updated clinical practice guidelines for assessment of cardiovascular risk, reduction of
risk through lifestyle modification, management of cholesterol, as well as overweight/obesity
management. One of the expert panels was tasked with providing current evidence based
foundation for primary and secondary prevention of atherosclerotic cardiovascular disease
(ASCVD) in men and women. Recommendations were made from data reviewed from
randomized control trials, systematic reviews, and meta-analysis of ASCVD literature.
Specifically, one work group was tasked to provide risk assessment input to expert panels for
cholesterol, blood pressure, and overweight/obesity guidelines (Goff et al, 2013). Their purpose
was to recommend a cardiac risk assessment model to these work groups. A rigorous review of
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risk assessment methodology for cardiovascular risk scores was conducted. Findings from
existing cardiac risk scores research used non-representative or data populations, had limited
ethnic diversity, narrowly defined endpoints, endpoints influenced by provider preferences (e.g.
revascularization), and endpoints with poor reliability (e.g. angina and heart failure) (Goff, et al
2013.
2013 ACC/AHA Guidelines
The Framingham Risk Score, recommended in the previous American Heart Association
guidelines, was found to be void of contemporary data, and dominated by a white population
with limited coverage of other ethnic groups (Preis and Kristensen, 2015). A more limited
outcome scope of coronary heart disease (CHD) and insufficient focus on ischemic stroke as a
cardiac risk score outcome were additional factors in the lack of endorsement of the Framingham
Risk Score to be used for cardiac risk assessment model in the 2013 American College of
Cardiology (ACC)/American Heart Association (AHA) Risk Assessment Guidelines (Goff et al.,
2013; Preis & Kristensen, 2015)
The Work Group developed a cardiovascular risk assessment equation called the Pooled
Cohort Risk Score Equation. The 2013 ACC/AHA Risk Assessment Guidelines included the
recommendations of the American Diabetes Association and the American Stroke Association
on a cardiac risk assessment model focused on the predicted estimation of ASCVD
(Atherosclerotic Coronary Disease) events (Goff et al., 2013). The Work Group developed the
Pooled Risk Cohort Equation that provided an estimation of risk for an initial Atherosclerotic
Coronary Disease event. Atherosclerotic cardiovascular disease (ASCVD) events were defined
as the first occurrence of non-fatal myocardial infarction or coronary heart disease death, or nonfatal and fatal stroke. The Pooled Cohort Risk Score was the clinical cardiovascular risk
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assessment score recommended in the 2013 ACC/AHA Risk Assessment Guidelines (Goff et al.,
2013) and 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce
Atherosclerotic Cardiovascular Risk in Adults (Jensen et al., 2014).
Pooled cohort risk Equation development. The Pooled Cohort Risk Equations was
developed using the prior experiences with the development of the Framingham Heart Study risk
prediction equations (NCEP, 2002; Wilson et al., 1998), and the Framingham Risk Score
cardiovascular disease risk prediction equation (D’Agostino, et al, 2008; Goff et al, 2013). Data
was used from several large, racially and geographically diverse cohort studies, including the
ARIC (Atherosclerosis Risk in Communities) study (Folsom et al, 2006), Cardiovascular Health
Study (Fried, et al., 1991), and the CARDIA (Coronary Artery Risk Development in Young
Adults) study (Friedman, et al., 1998). The use of pertinent data from the Framingham Original
and Offspring Study cohorts (Dawber, Kannel, & Lyell, 1963; Kannel, Feinleib, McNamara,
Garrison, & Castelli, 1979) was used with the goal of expanding the utility and generalizability
of the Pooled Cohort Risk Equations (Goff et al., 2013). Risk factors with statistical justification
for inclusion in the risk assessment equations were age, total and high-density lipoprotein
cholesterol, systolic blood pressure (including treated or untreated status), diabetes, and current
smoking status. In addition to the traditional risk factors, the inclusion of the novel risk factors of
high-sensitivity C-reactive protein (hs-CRP), apolipoprotein B (ApoB), glomerular filtration rate
(GFR), micro albuminuria, family history, cardiorespiratory fitness, ankle-brachial index (ABI),
carotid intima-media thickness (CIMT), or coronary artery calcium (CAC) were evaluated. The
outcome of ten-year cardiovascular risk was defined as the risk of developing a first
atherosclerotic cardiovascular disease (ASCVD) event (nonfatal myocardial infarction, or
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coronary heart disease (CHD) death, or fatal or nonfatal stroke) among individuals free from
prior ASCVD (Goff et al., 2013).
Inclusion criteria were the following: 40 to 79 years of age, and apparently, free of
history of nonfatal myocardial infarction, stroke, heart failure, percutaneous coronary
intervention, coronary artery bypass surgery, or atrial fibrillation. A total of 11,240 white women
(who experienced 902 events), 9,098 white men (1,259 events), 2,641 black women (290
events), and 1,647 black men (238 events) comprised the population to develop sex-and racespecific equations to predict 10-year risk for a first hard atherosclerotic cardiovascular disease
(ASCVD) event (Goff et al., 2013).
The performance of the risk score in predicting atherosclerotic cardiovascular disease
(ASCVD) was assessed using development cohorts (specifically, most recent examination cycles
from Atherosclerosis Risk in Communities Study (ARIC) and the Framingham Heart Study for
which 10 years of follow up is available) and external cohorts consisted of whites and blacks
from the Multi-Ethnic Study of Atherosclerosis (MESA) and the Reasons for Geographic And
Racial Differences in Stroke Study (REGARDS) (Howard, et al., 2005). However, both the
MESA and REGARDS study had less than 10 years of follow up data (Goff et al, 2013). For
MESA, a 6-year rate of cardiac event occurrence was used, while a 4-year rate was used for the
REGARDS (Goff et al, 2013).
Sex and race specific Cox proportional hazard models including age, systolic blood
pressure (treated and non-treated), total cholesterol, high-density lipoprotein, smoking status (yes
or no), and diabetes (yes or no) were used to develop the Pooled Cohort Risk Equations. As seen
in Table 2, the calibration of the models ranged from a low C-statistic of C= 0.71 for black men
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2

to C = 0.81 for black
2

= 4.86 for non-

= 7.25 for black women (Goff et al., 2013).

Table 2. Pooled Risk Equations Calibration and Discrimination for White and Black Men and
Women from the Derivation and External Cohorts.
n

C

2

n

Black females
Derivation
MESA
REGARDS

2641
978
5275

0.81
0.76
0.70

Black males
7.2
18.51
48.22

1647
799
2969

White females
Derivation
MESA
REGARDS

11240
1273
6333

0.80
0.71
0.65

2

C

.71
.66
.55

6.71
24.40
46.28

White males
6.43
14.56
44.93

9098
1184
5296

.74
.70
.59

4.86
21.43
66.71

Note. C2 = Hosmer-Lemeshow Chi Square Statistic; MESA = Multi-Ethnic Study
of Atherosclerosis; REGARDS = Reasons for Geographic and Racial Differences in Stroke Study.

The number of predicted cardiac events compared to the actual events was over predicted
in all of the validation groups. Calibration chi-squared statistics were well above the threshold of
20 for white men and women as well as black men and women from the REGARDS population
due to a low observed event rates at higher predicted risk. The 4-year prediction window for
REGARDS may have been a factor in the poor validation results. The derivation cohort
consistently demonstrated greater discrimination than the validation cohorts. However, there was
overall lower discrimination and over prediction in the validation samples. The absence of other
ethnicities and low number of blacks, particularly men, limits the applicability of the equations to
other populations, in particular to lower risk populations, such as Asians or Hispanics/Latinos
(Goff et al., 2013). Given the requisite for new prediction model scores needed for external
validation, Muntner, et al., (2014) assessed the calibration and discrimination of the Pooled
Cohort Risk Equation in a contemporary population-based cohort from the Reasons for
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Geographic and Racial Differences in Stroke (REGARDS) study. Analysis on the REGARDS
population (n=18,498) without atherosclerotic cardiovascular disease at baseline was conducted.
Additional analysis of a sub-population (n=10,997) for which the Pooled Cohorts Risk Equations
were intended to provide information for initiating statin use (participants without clinical
atherosclerotic cardiovascular disease or diabetes, with low-density lipoprotein cholesterol levels
between 70 and 189 mg/dL, and not taking statins) was also preformed (Muntner, 2014).
The REGARDS study conducted in January 2003 and October 2007 with follow up
through December 2010 did not have active surveillance of atherosclerotic cardiovascular events
(e.g., review of hospital discharges and obituaries in local newspapers) to detect atherosclerotic
cardiovascular disease events not reported by participants. To address this limitation,
cardiovascular disease events identified in Medicare claims data were used to supplement routine
cohort follow-up. The Medicare system provides health insurance to adults ages 65 years or
older, and to those with end stage renal disease or disability.
The predicted number of events consisting of nonfatal myocardial infarction, coronary
heart disease (CHD) death, and nonfatal or fatal stroke) was calculated based on the mean
predicted atherosclerotic cardiovascular disease incidence at 5 years. Observed and predicted
atherosclerotic cardiovascular disease incidence rates at 5 years within the 4 atherosclerotic
cardiovascular disease risk groups were used since the REGARDS study had not completed the
10 years of follow up. Participants were categorized according to their 10-year predicted
atherosclerotic cardiovascular disease risk: less than 5%, 5% to less than 7.5%, 7.5% to less than
10%, and 10% or greater. Participants were grouped into deciles of predicted atherosclerotic
cardiovascular disease risk. Calibration was determined using observed and predicted number of
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2

events at 5 years of follow up with a Hosmer-

statistic. C-statistics were calculated

to estimate discrimination of the Pooled Cohort Risk Equations.
The predicted five-year atherosclerotic cardiovascular disease was calculated using the
Pooled Cohort Risk Equations. At 5 years of follow-up, 53.6 %of REGARDS participants were
free of atherosclerotic cardiovascular disease events. Individual 10-year atherosclerotic
cardiovascular disease risk was calculated using the Pooled Cohort Risk Equations.
Table 3. Pooled Cohort Risk Equations Discrimination and Calibration Statistics by Gender and
Race.
N

2

p

C

Overall
Men
Women
Black
White

18498

84.2
62.8
27.9
41.9
44.1

< .001
< .001
< .001
< .001
< .001

.71
.65
.74
.68
.72

Overall (S)
Men
Women
Black
White

10997

19.9
16.5
8.3
11.8
14.0

.01
.04
.41
.16
.08

.72
.66
.75
.69
.74

Medicare
Medicare (S)

6121
3333

11.4
5.4

.18
.71

.65
.67

Note. (S)= Subgroup,
Statistically Significant.

-Lemeshow Chi Square statistic, C-Statistic = Harrell’s C Statistic. p < .05 =

In the overall cohort, there were 674 atherosclerotic cardiovascular disease events (382
coronary heart disease events and 292 strokes). Calibration for the overall population was poor
(Hosmer-Lemeshow

2

= 84.2, p < .001). Risk was overestimated for white and black men and

women. The C-statistic for the overall population was 0.71, 95% CI [0.69- 0.72] and
discrimination of risk was better in women compared with men and whites compared with
blacks.

57

Among the individuals in the subgroup (n=10,997), for whom statin treatment should be
considered based on atherosclerotic cardiovascular disease risk, there were 338 atherosclerotic
cardiovascular disease events (192 coronary heart disease events and 146 strokes). Calibration
was better indicating greater precision in the estimation of cardiovascular disease risk (HosmerLemeshow

2

= 19.9, p = .01). Furthermore, the Hosmer-Lemeshow
2

= 8.3, p = .41), blacks (

2

2

indicated good calibration
2

= 11.8, p

= 14.0, p = .08). The

C-statistic was 0.72, 95%CI [0.70-0.75] and indicated better discrimination among women and
whites compared with men and blacks.
In individuals with Medicare-linked data from the overall REGARDS population (n =
6,121), of the 457 atherosclerotic cardiovascular disease events (225 coronary heart disease
events and 232 strokes), 112 of these events were identified in Medicare claims. Within the subpopulation of those individuals with Medicare linked data (n=3,333), 57 included in the 234
atherosclerotic cardiovascular disease events (120 coronary heart disease events and 114
2

strokes,) were identified in Medicare claims. The Hosmer-Lemeshow
calibration in the overall population of Medicare
subgroup Medicare linked individuals

2

2

indicated good

= 11.4, p = .18) and in the

= 5.4, p = .71). For both groups of Medicare-linked

individuals, a C-statistic of .67 in the overall population and a C-statistic of .65 in the sub-group
indicated poor discrimination. Medicare patients are those individuals 65 years and older and/or
those with end-stage renal disease or disability.
DePhilips et al. (2015) compared the calibration and discrimination of the Pooled Cohort
Risk Equations endorsed by American Heart Association (AHA) and American College of
Cardiology (ACC) with the Framingham Risk Score to predict coronary heart disease (FRSCHD), as well as the Framingham Risk Score to predict cardiovascular disease (FRS-CVD), The
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ATP III Risk Score (Grundy et al., 2004) and Reynolds Risk Scores were used to explore
preventive therapy and perhaps identify a cause of the reported risk overestimation from the
Pooled Cohort Risk Equations. The use of common preventive therapies of aspirin, lipidlowering or antihypertensive therapies, and revascularization were investigated as the cause of
overestimation of the Pooled Cohort Risk Equations.
The Multi Ethnic Study of Atherosclerosis (MESA) (2000 to 2002) cohort included a
diverse sample of 53.5% women, 42% whites, 26% blacks, 20% Hispanics, and 12% Chinese
(see Folsom et al., 2008). The mean age of the participants was 61.5 years old. Participants were
free of clinical CVD at enrollment. Discrimination and calibration were assessed using the
endpoints/events for the Pooled Cohort Risk Equation, and the respective end points for the other
cardiovascular risk score. Observed events included in the assessment occurred within 10.2 years
of follow-up in MESA. Additionally, 3,175 MESA participants included in the Part A hospital
claims within the Centers for Medicare & Medicaid Services (CMS) billing database were
reviewed in order to identify any atherosclerotic cardiovascular events not used in the MESA
study. However, diabetics were excluded from analyses due to inability to calculate risk scores
using the ATP III and RRS for men.
The Hosmer-Lemeshow

2

statistic was used to assess the calibration and Harrell’s C-

statistic was used to assess discrimination. The FRS-CHD, FRS-CVD, ATPIII-FRS-CHD, and
the Pooled Cohort Risk Equations overestimated risk for their designated cardiovascular end
points in men and women. The Reynolds Risk Scores demonstrated the least discordance in
predicted and observed risk in all men and women. Overestimation was across low, intermediate
and high deciles of cardiovascular risk. The authors point out that their analysis indicated that
women tended to have less overestimation than men in these models. The FRS-CVD, RRS, and
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Pooled Cohort Risk Equations had adequate discrimination in men and women. DeFillips et al.,
(2015) did not report analyses by race. The reported over prediction and discriminatory ability of
risk scores is presumed to be across race and gender. Additionally, the use of common
preventive therapies (aspirin, lipid-lowering or antihypertensive therapy, and revascularization)
did not explain the overestimation by the Pooled Cohort Risk Equations (DeFillips et al., 2015).
The recent research conducted by DeFillips et al. in 2015, was the most similar to the
present study conducted. However, this research excluded the Framingham Risk Score to predict
coronary heart disease (FRS-CHD), and the ATP III (Adult Treatment Panel) risk score.
Discrimination and calibration analyses differed, and analyses were conducted by race and
gender. Additionally, the Heart SCORE study had more recent data that included cardiovascular
events.
According to Preis & Kristensen, (2015) the strengths of the Pooled Cohort Equations
included better risk prediction with the inclusion of race, especially in black individuals, and the
inclusion of stroke as a cardiac endpoint. However, the important risk factors of chronic kidney
disease and social deprivation were not included. Lastly, atherosclerotic cardiovascular disease
(ASCVD) risk was overestimated, which might result in statin therapy being prescribed to many
individuals based on joint American College of Cardiology/ American Heart Association
guidance on cholesterol treatment (Preis & Kristensen, 2015).
Other Cardiovascular Risk Scores
The same cardiovascular risk factors used in the Framingham risk score, Reynolds Risk
Score for women, Reynolds Risk Score for men, and the Pooled Cohort Risk Equations (see
Table 1) are used in Europe. The PROCAM (Prospective Cardiovascular Munster Study) and
British (Brindle et al., 2003) adapted the Framingham Risk equation (Anderson et al., 1991) to
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assess global cardiovascular disease risk. The risk score developed in 2007 called the QRISK
score (Hippisley-Cox et al., 2007) was formulated in the United Kingdom from over 1 million
non-diabetic participants. The QRISK risk score developed in 2007 incorporated the
Framingham risk factors, family history, and social deprivation. The risk score ASSIGN was
developed using the SIGN guidelines to identify and assign patients to preventive treatment in
the United Kingdom. The risk score algorithm was developed with individuals from the Scottish
Heart Health Extended cohort (Woodward et al., 2007). The ASSIGN score incorporated family
history and social deprivation in addition to Framingham risk factors (D’Agostino et al., 2008).
These risk scores developed in Britain and Scotland, which incorporated family history
and social deprivation as risk factors, provide additional, yet minimal, accuracy in cardiovascular
risk assessment when compared to the Framingham Risk Score in the British and Scottish
population (Dhinger & Vasan, 2012). Cardiovascular risk scores developed in Britain
(Hippisley-Cox, et al., 2007), Scotland (Woodward et al., 2007), and China (Zhang, Attia,
D'Este, Yu, & Wu, 2005) have not been formally tested in the United States (Dhinger & Vasan,
2012).
Chapter Summary
The literature review synthesizes known racial disparity in the prevalence of
cardiovascular risk factors. A large percentage of prior research studies have been comprised of
predominately white study populations. Given the high and often differential prevalence of
cardiovascular risk factors among blacks and Hispanics, their inclusion in cardiovascular
research is critical. The underrepresentation of non-white participants hinders the acquisition of
knowledge to formulate adequate cardiovascular prevention that is fully applicable across races.
The Heart SCORE population included nearly equal number of white and black participants.
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Applying the Heart SCORE population to the Framingham Risk Score, Reynolds Risk Score for
women, Reynolds Risk Score for men, and the Pooled Cohort Risk Equation models is expected
to contribute to the knowledge of cardiovascular risk among white and black men and women.
The search for new risk factors is an important component of cardiovascular research.
The examination of any incremental value to risk prediction model may be ascertained.
Therefore, the inclusion of the variables carotid intima media thickness (CIMT), peripheral
artery tonometry (PAT) and vasa vasorum (VV) to cardiovascular risk models may provide
additional knowledge leading to optimal management of intermediate risk patients.
Additionally, the application of a population that was not used to derive the risk score
permits an additional assessment of risk model performance. The application of the Heart
SCORE population to the Framingham risk score, Reynolds Risk Score for women, Reynolds
Risk Score for men, and Pooled Cohort Risk Equations provides new information and
knowledge. The Pooled Cohort Risk Equations is the newest of the cardiovascular risk scores
used in this research. The application of a novel population is especially informative.
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CHAPTER 3: METHODS
Chapter 3 details the quantitative research methodology of this large prospective cohort
study, including the following topics: research design, sample, measures of study variables, the
plan for data management and analysis, and ethical protections for participants.
Study Design
Heart Strategies Concentrating On Risk Evaluation (Heart SCORE) is a longitudinal
prospective cohort study conducted over a ten year time period. Secondary data analysis using
the Heart SCORE dataset permits examination of extensive information about cardiovascular
risk factors to identify scientific areas that might need further research, as well as to examine
important current clinical questions. These activities can be achieved within a short time and
with minimal resources. The use of this comprehensive dataset for novel research aims yielded
new information on cardiovascular risk and risk stratification, consistent with the intent for
which this study was initially conceived and was subsequently carried out.
Secondary Analysis
For this secondary analysis, permission form the Heart SCORE investigators at the
University of Pittsburgh to conduct a secondary data analysis was requested and granted. A
committee member for this research was involved in Heart SCORE research at the University of
Pittsburg. Heart SCORE data was accessed from the online Heart SCORE database using a
passcode protected site. With the given permissions and passcode, Dr. Kevin Kip obtained a deidentified dataset which was copied and provided to the primary investigator for analysis. The
original de-identified datasets and subsequent analysis files are included on password-protected
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computers of Dr. Kip and the primary investigator Johanna Wilson. No other persons on the
research committee had copies or access to the de-identified datasets or subsequent analyses files
for this research study.
Protection of Human Subjects
Prior to its initiation, the Heart SCORE study was submitted and approved by the
University of Pittsburgh Institutional Review Board. The current research for secondary data
analyses was submitted and approved by the University of South Florida Institutional Review
Board. From the parent study (Pittsburgh), participants responded to a recruitment letter,
advertisement or public announcement regarding the Heart SCORE study and called the
recruitment office. Recruiters then explained the study to interested persons. These persons were
then invited to a study visit where informed consent was signed, eligibility was confirmed, and
they met with a research coordinator and/or co-investigator. All participants were provided with
a copy of their signed informed consent. The initial meeting included detailed review of the
study description including all measures to be completed and schedule of follow-up.
Study Setting
Primary Research Site
All Heart SCORE data collection and research activities were conducted at the University
of Pittsburgh Medical Center (UPMC) Cardiovascular Institute in Pittsburgh, PA. Participants
were assigned a study identification number to preserve anonymity. All information related to
the study was stored in a locked files at the UMPC Medical Center and on a password-protected
secure server.
Heart SCORE recruitment. Heart Strategies Concentrating On Risk Evaluation (Heart
SCORE) is a multi-faceted community-based participatory research program designed to address
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cardiovascular disease (CVD) by improving risk stratification, identifying racial disparities, and
evaluating a multidisciplinary community-based intervention program to decrease CVD risk in
high-risk populations (Kip et al., 2005). The Heart SCORE study is still ongoing with long-term
data collection in progress for the cohort of 2,000 participants who were enrolled from western
Pennsylvania. By study design, there is nearly equal representation of White and Black subjects.
The a priori specified recruitment goals included enrollment of 2000 participants (~50% black),
including 800 participants at low Framingham risk, 1,000 participants at intermediate or high
Framingham risk, and 200 participants with established cardiovascular disease.
Subject eligibility criteria included age 45 to 75 years, residence in the greater Pittsburgh
metropolitan area (~50 mile radius), an ability to undergo baseline and annual follow-up visits,
and absence of known comorbidities expected to limit life expectancy to less than five years.
Recruitment procedures included targeted mailings by zip code, advertisements, referrals,
and direct promotion through community organizations. This included recruitment from
community-based blood pressure and lipid screening programs, educational seminars at places of
worship, and community centers. There was purposeful emphasis on recruitment of traditionally
underserved and high-risk communities, which was achieved through partnerships with the
Cardiovascular Institute at the University of Pittsburgh, Metro-Urban Institute Office of Applied
Religion (MUI-OAR) of the Pittsburgh Theological Seminary, the Urban League of Pittsburgh,
and other community-based and academic partners. Additional details of the Heart SCORE study
have been published (Kip et al., 2005).
Heart SCORE data collection. The current research study leverages use of information
provided by the wealth of data captured from the Heart SCORE study. Demographic, clinical and
biological variables were extracted from the Heart SCORE dataset. At the baseline visit, the
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detailed demographic variables, of age, gender, race, and ethnicity were obtained from Heart
SCORE participants via self-report (Appendix A). Race and ethnicity were classified utilizing
categories defined by the U.S. Census Bureau and were collected via self-report. Measures of
social economic status were obtained via self-report items regarding educational attainment and
annual household income (Appendix B). Physical examination included vital signs and
anthropometric measures and was measured continuously throughout the study.
Blood pressure was measured using a standard protocol, as previously described by
Aiyer, et al., (2007). Diabetes mellitus was defined as fasting glucose >126 mg/dL or a reported
history of previously diagnosed diabetes treated with diet, oral agents, and/or insulin.
Hypertension was defined as a systolic blood pressure of >140 mmHg, diastolic pressure of >90
mmHg, history of physician-diagnosed hypertension, or current use of anti-hypertensive
medication.
At the baseline visit, fasting blood samples were drawn into tubes containing EDTA by
venipuncture. Serum total cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol,
and low-density lipoprotein (LDL) cholesterol were obtained using the vertical automated profile
(VAP) (Atherotech, Inc., Birmingham, AL, USA). Fasting plasma insulin levels were determined
using an immunoenzymatic method (Abbott, Abbott Park, IL, USA) and fasting glucose
concentrations were measured by glucose oxidase method.
Following the baseline examination, a summary of the subject’s risk factor profile, based
on the NCEP ATP-III ("Executive Summary of The Third Report of The National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol In Adults (Adult Treatment Panel III)," 2001) and JNC7 (Chobanian et al.,
2003) guidelines, were provided to their primary care physician. Subjects who did not have an
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established relationship with a healthcare provider were referred to family practitioners or
general internists, including the Metro Family Practice, Inc. (MFPI, Wilkinsburg, PA), a
501(c)(3) comprehensive primary care organization that provides healthcare for uninsured
patients (Kip et al., 2005).
Cardiovascular Disease Risk Factors
Biological measures of cardiovascular risk were obtained by laboratory assessments of
blood pressure to assess the presence of hypertension, and by a fasting blood sample to obtain
glucose concentrations in order to evaluate the metabolic syndrome (Appendices C, D, and E).
Total cholesterol, low-density lipoprotein and high-density lipoprotein, cholesterol, and
triglyceride level were collected (Appendix E) in addition to high sensitivity C-reactive protein
(hs-CRP) collected at the baseline evaluation. The risk factors collected by self-report included
smoking cessation, having taken blood pressure medication in the last 48 hours, history of
coronary artery disease, and family history of coronary artery disease (Appendices F, G, and H).
Different cardiovascular risk factors are used to calculate a Framingham Risk Score,
Reynolds Risk Score for women, Reynolds Risk Score for men and Pooled Cohort Risk Score.
Cardiovascular risk factors of age, sex, total cholesterol, high-density lipoprotein, systolic blood
pressure, blood pressure treatment, diabetes mellitus, and smoking are utilized to calculate a
Framingham Risk Score. The Reynolds Risk Scores are calculated with the appropriate sex for
each risk score in addition to age, total cholesterol, high-density lipoprotein, low-density
lipoprotein, systolic blood pressure, smoking, and high sensitivity C-reactive protein. Age, total
cholesterol, high-density lipoprotein, systolic blood pressure, blood pressure treatment and
smoking are used to calculate the Pooled Cohort Risk Score. These cardiac risk factors used to
predict an individual’s risk for cardiac events over ten years are specified for each cardiovascular
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risk score. The predicted cardiac events known as cardiovascular risk model outcomes are also
specific to the cardiovascular risk score.
Cardiovascular Risk Model Outcomes
The Framingham Risk Score, Reynolds Risk Scores and Pooled Cohort Risk Score
predict different cardiovascular risk model outcomes. The 2008 Framingham Risk Score
outcomes include: MI, stroke, death due to stroke, death due to coronary heart disease (CHD),
and heart failure. For the Reynolds Risk Scores (women and for men), outcomes used include
revascularization, MI, death due to coronary heart disease, stroke and death due to stroke. The
Pooled Risk Score Equations aimed to assess risk for an initial atherosclerotic cardiovascular
disease (ASCVD) event: nonfatal myocardial infarction or coronary heart disease, (CHD) death,
or fatal or nonfatal stroke (Goff et al., 2014). Analysis within the present study used
cardiovascular risk model outcomes that were consistent across all three cardiovascular risk
scores.
Heart SCORE Cardiovascular Events
Heart SCORE follow-up cardiovascular events were collected over the course of the
study period. Follow-events include: death, myocardial infarction, stroke (Acute Ischemic Stroke
(AIS), stroke (not AIS), cardiac failure/congestive heart failure; revascularization (Coronary
Artery Bypass Graft (CABG) or Percutaneous Coronary Intervention (PCT), arrhythmia, other
vascular events (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Peripheral
Artery Disease (Peripheral Artery Disease) (Appendices I and J).
Throughout the entire follow-up period, cardiovascular events experienced by Heart
SCORE study subjects were diligently monitored and classified through an adjudication board.
In August of 2014, the number of adjudicated events experienced by the participants was
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updated in Heart SCORE database. A total of 222 adjudicated events occurred. These events
were used in the statistical analysis to determine the calibration and discrimination of the
cardiovascular risk scores.
Table 4. Heart SCORE events for Framingham Risk Score, Reynolds Risk Scores and Pooled
Cohort Risk Equations Risk Score Outcome
Risk score outcome
MI (non-fatal)
MI Death
Stroke (non-fatal)
Stroke Death
Revascularization

Event
MI
MI Death
Stroke & AIS
Stroke Death, AIS Death
PCI & CABG

Note. MI=myocardial infarction, AIS= Acute Ischemic stroke, CHF= Congestive Heart Failure, PCI= Percutaneous
Coronary Intervention, CABG= Coronary Artery Bypass Graft

Heart SCORE Novel Cardiovascular Risk Factors Data Collection
With its emphasis on better quantifying cardiovascular risk, Heart SCORE included 3
relatively novel measures that serve as surrogates for atherosclerosis and cardiovascular risk.
These included measures of carotid intima-media thickness, endothelial function by use of
peripheral arterial tonometry, and vasa vasorum, as described below. Carotid ultrasound
imaging, pulse amplitude tonometry, and non-linear ultrasound were used to obtain biological
measures of the novel cardiovascular risk factors. As these were conducted after the initiation of
Heart SCORE, their data collection forms were not included in the original study forms.
Carotid intima media thickness. Carotid artery imaging was carried out using a GE
VIVID7 (General Electric Corp.) ultrasound imaging system and a 7MHz linear array vascular
ultrasound probe. The ultrasound beam was adjusted to obtain longitudinal scans of the carotid
arteries to visualize two parallel echogenic lines corresponding to the 5 blood-intima and mediaadventitia interfaces on the posterior wall. End-diastolic images were recorded using
electrocardiographic gating. Software on the GE VIVID 7 was used to calculate intima-media
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thickness (IMT) using automated edge detection to locate the lumen-intima and media-adventitia
echo boundaries at subpixel resolution. 29 MT was averaged over 70-100 individual
measurements taken along a 1-cm segment of the common carotid artery beginning 0.5 cm from
the carotid bifurcation along the far wall of the distal common carotid artery. Significant carotid
intima-media thickness (CIMT) was defined as maximal CIMT>1 mm in either the right or left
carotid artery, as previously described by others (Spence, 2006). A subset of Heart SCORE
participants (n = 739) who received CIMT assessment were used for this research.
Peripheral arterial tonometry. Endothelial function was measured via a (Reactive
Hyperemia) (RH)–PAT index. The RH protocol consists of a 5 min baseline measurement, after
which a blood pressure cuff on the test arm was inflated to 60 mmHg above baseline systolic
blood pressure or at least 200 mmHg for 5 min. Occlusion of pulsatile arterial flow was
confirmed by reduction of the PAT tracing to zero. After 5 minutes, the cuff was deflated, and
the PAT tracing was recorded for a further 6 min. The ratio of the PAT signal after cuff release
compared with baseline was calculated through a computer algorithm automatically normalizing
for baseline signal and indexed to the contra lateral arm. The calculated ratio reflects the
Reactive Hyperemia Index (RHI). The natural logarithmic scaled RHI (L_RHI) was calculated
from the same ratio between the digital pulse volume during RH and baseline Framingham Risk
Score (FRS). A PAT measurement was obtained in 1,382 of the 2,000 Heart SCORE participants
Vasa vasorum. Prior to the conducting vasa vasorum assessment in Heart SCORE,
which is very new clinical technique, a preclinical study to validate the use of carotid ultrasound
for quantification using serial evaluations of adventitial vasa vasorum was conducted on 20 New
Zealand white rabbits. The rabbits were fed a high-fat diet for 3 weeks. After the initial week of
feeding, bilateral femoral artery stenosis were induced by balloon injury. Non-linear ultrasound
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imaging (10 MHz) was performed at 2, 4, and 6 weeks post-injury during intravenous micro
bubble injection using destruction-replenishment to quantify blood velocity (Beta) and volume as
peak video intensity. At baseline and 2, 4, and 6 weeks post-injury (n=5 rabbits per group), both
femoral arteries were sectioned (40 vessels) and stained to identify endothelium. Adventitial vasa
vasorum were quantified by counting the number of stained micro vessels. Plaque size was
measured from histology. Histologic results from this experiment demonstrated that
atherosclerotic plaque progressed over 6 weeks (p<0.0001), with near total occlusion by 6 weeks
(98±3% luminal stenosis). Total number of adventitial neovessels overlying the atherosclerotic
plaques (i.e., vasa vasorum) of these vessels significantly increased from baseline (P<0.0001). In
the rabbits allowed to survive for 6 weeks and in whom serial CU imaging was performed at 0, 2,
4, and 6 weeks, there was a progressive increase in peak video intensity over time (p<0.0001),
suggesting that neovascularization parallels atherosclerosis progression.
On the basis on this emerging use of measurement of vasa vasorum, a total of 581 (out of
2,000) subjects in Heart SCORE underwent carotid ultrasound measurement of both carotid
arteries to quantify adventitial vasa vasorum. Peak video intensity in the arterial wall after micro
bubble contrast injection was measured in these subjects. The normalized to peak luminal video
intensity were measuring using the methods tested in the rabbit model. This information was not
published, but available through the Heart SCORE study.
The measures pulse amplitude tonometry (PAT), carotid intima media thickness (CIMT)
and vasa vasorum (VV) were implemented part-way into the Heart SCORE study, and not all
participants had these measure completed. Importantly, the Heart SCORE data set permits the
linking of these variable with other measures, such as baseline, 1-year, 2-year assessment, etc.,
using the variables which indicate the date these measures were taken “PAT date”, “IMT date”,
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and “VV date”. Therefore, the variables from the follow up assessment completed closest to
these variables will be selected. The Heart SCORE participants were enrolled from June 2003 –
October 2006. Pulse Amplitude Tonometry (PAT) measurements were obtained in January of
2004 until October of 2006. Participants completed the carotid intima media thickness (CIMT)
measurement and/or vasa vasorum (VV) measurement in January 2008 until April 2011.
Statistical Analysis
Overview
Baseline characteristics of Black and White participants were compared using chisquared tests for categorical variables and student’s t test or Wilcoxon Rank Sum Test for
continuous variables. Variable normality was assessed for all continuous variables and those
with skewed distributions were log-transformed to approximate normal distribution, before
application of the t-test or fitting regression models. Multicolinearity of covariates (independent
variables) was examined to avoid model over fitting. For evaluating performance of the
individual risk scores, a survival analysis approach was used with Cox proportional hazards
regression as the primary multivariable method. All observations were equally weighted in the
analysis.
The most common method for deriving cardiovascular risk score model fit statistics to
assess risk score performance with the C-statistic/aROC (area under the receiver operating curve)
and Hosmer-Lemeshow X2 are based on logistic regression (Chamnan, et al. 2r009). Logistic
regression assesses the proportion of new cases that develop in a time period. However it does
not take into account subjects lost to follow up or who withdraw. Survival analysis (Cox
regression) assesses the hazard rate, which is the number of new cases/events per population at
risk per unit of time of events (SAS, 1999). As referenced above, logistic regression ignores the
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time-dependent nature of cardiovascular risk assessment modeling and the impact of loss to
follow-up. Pencina and D’Agostino (2004) and Chambless and Diao (2006) recommended the
performance of a risk score estimated from survival data in the presence of censoring (Chamnan,
et al., 2009). In longitudinal research studies (such as Heart SCORE), investigators follow
participants for a set time period or until a pre-specified endpoint (event) is reached. Participants
often withdraw from the study or reach the endpoint prior to the end of the specified follow up
time. Logistic regression does not adjust address participant withdraw or occurrence of a
premature event/endpoint (Boston University, 2016). Censoring is used in Cox regression
analysis to include participants who withdraw and those with a premature event/endpoint.
In Cox proportional regression model several covariates (risk factors) are considered
simultaneously to examine survival time (Tabachnick & Fidell, 2007). Assumptions of Cox
proportional hazard models include constant relative risk during the study period, and a
multiplicative relationship between predictors and hazards (Boston University, 2016). The
hazard ratio is the total number of observed events in to independent group comparisons (SAS,
1999). An assumption of the Cox proportional regression hazard model is the independent
survival time function (time until an event) for each participant in the sample. An individual
survival function as opposed to one fixed survival function for the study population permits the
comparison of the survival functions of the subpopulations (e.g. black males, white females).
The hazard rate (the risk of suffering the event of interest given that the individual survived to
the specific time point) can be assessed for the subpopulations (SAS, 1999).
Cardiovascular Risk Model Performance
For this research cardiovascular risk model performance (calibration and discrimination)
were not assessed using the Harrell’s C-statistic or the Hosmer-Lemeshow X2 produced by

73

logistic regression. Instead, the focus was on the use of survival analysis methods of visual
examination of plots of calibration.
Discrimination. Discrimination analysis was used to assess the ability of the
cardiovascular risk scores to assign a higher risk score to those who experienced the
cardiovascular event or myocardial infarction (MI), death, stroke, Acute Ischemic Stroke (AIS),
or revascularization (coronary artery bypass grafting or percutaneous coronary intervention
compared to those who did not experience a CVD event. The cardiovascular risk scores assigned
to each woman and man were split into quintiles for the Framingham Risk Score, Reynolds Risk
Score for women, Reynolds Risk Score for men, and Pooled Cohort Risk Equations. The
cardiovascular risk scores of the participants who experienced the cardiovascular events were
also split into quintiles of risk. A Wilcoxon Rank Sum Test was conducted for statistical
significance of discrimination ability of the overall cardiovascular risk scores, and discrimination
ability by race and gender. Discrimination was visually assessed with the box plots of the
Wilcoxon Rank Sum test for the risk cardiovascular risk.
Calibration. Calibration reflects prediction accuracy. A well-calibrated risk score assigns
the correct probability of an event at all levels of predicted risk (Royston and Altman, 2013). The
ability of the respective cardiovascular risk scores to accurately predict the risk of a
cardiovascular event in 10 years across the all levels of predicted cardiovascular risk was
assessed. The predicted risk scores of the Framingham Heart Score, Reynolds Risk Score, and
Pooled Cohort Risk Equations) were divided into quintiles. The mean predicted risk score was
calculated for each quintile.
The cardiovascular risk scores of the individuals who experienced the cardiovascular
event were divided into quintiles for each of the cardiovascular risk scores. The mean observed

74

risk score was calculated for each quintile. The average follow up time for the Heart SCORE
participants was eight years. Therefore, in order to adjust for the average follow up time of less
than 10 years, the observed mean risk score of each quintile was divided by 0.8. Calibration was
assessed visually with the comparison of the mean predicted risk scores and mean observed risk
scores for the quintiles for each cardiovascular risk score.
Specific Aims
Aim 1. The first aim was to examine the overall predictive utility of the Framingham
cardiovascular risk score, Reynolds Risk Score for Women, Reynolds Risk Score for Men and
the Pooled Cohort Risk Equations using methods of calibration and discrimination. A
Framingham Risk score, Reynolds Risk Score for Women, Reynolds Risk Score for Men and the
Pooled Cohort Risk Equations was calculated using respective publicized risk algorithms
(Appendices J, K and L) These scores served as the primary independent variable (in separate
models) in relation to risk of incident cardiovascular disease events modeled by use of Cox
regression analysis. Thus, three cardiovascular risk scores were calculated for each woman and
man in the Heart SCORE population.
Aim 2. The second aim was to examine the overall predictive utility by race of the
Framingham Risk score, Reynolds Risk Score for Women, Reynolds Risk Score for Men and the
Pooled Cohort Risk Equations using methods of calibration and discrimination. The analytic
approach for this aim parallels that for Aim #1. However, analyses were stratified by race to
examine whether the different risk scores appear to perform differently when stratified by race.
Aim 3. The third aim was to assess the predictive utility of the Framingham Risk score,
Reynolds Risk Score for Women, Reynolds Risk Score for Men and the Pooled Cohort Risk
Equations with the inclusion of the variables carotid intima media thickness (CIMT), pulse
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amplitude tonometry (PAT), and/or vasa vasorum (VV). From Aims 1 and 2, the relative
performance of the individual risk scores was estimated overall and by race and gender. The next
step was to examine whether performance of these risk scores were significantly improved by the
addition of the three “novel” cardiovascular disease risk measures. The models (overall and
stratified by race and gender) included the individual risk score derived from the published
algorithms. Then, the variables CIMT, PAT and/or VV were forced into separate models to
assess the extent to which they provided unique predictive value when modeling the risk of CVD
outcomes. For all Cox regression models fit, the assumption of proportional hazard ratios was
examined and found to be satisfactory. Additionally with the inclusion of the novel risk factors,
the Akiake Information Criterion (AIC) (Akaike, 1973) was calculated to examine the net
improvement in model and risk score performance with respect to risk of CVD outcomes. The
AIC was founded on Shannon’s Information Theory (1948) and evaluates the goodness of fit of
the model, and the complexity of the model. A lower AIC indicates a better model fit. Estimates
of model fit can be compared between models so long as the same subjects are used in each
model.
Chapter Summary
A secondary data analysis of the longitudinal study Heart SCORE was selected for this
study. This chapter has presented the details of the study design, target population, recruitment,
target population, research setting, variables, and statistical analysis. Statistical analyses to
address the research aims for this research included descriptive statistics, t-tests, Wilcoxon Rank
Sum Tests, and Cox regression analysis. Of key emphasis was the comparison of published risk
score models in relation to risk of cardiovascular disease outcomes within Heart SCORE,
including stratification by race and gender, and examination of incremental value of the variables
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carotid intima media thickness (CIMT), pulse amplitude tonometry (PAT) and/or vasa vasorum
(VV) to the risk scores. Additionally data collection methods, human protection strategies, and
ethical considerations were also presented for this study. The results of the study are discussed in
Chapter 4.
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CHAPTER 4: RESULTS

Introduction
This chapter provides a descriptive summary of the study participants and the results of a
secondary data analysis of the Heart SCORE dataset (a longitudinal prospective cohort study
conducted over ten years). The data set consisted of 1,949 participants of the total 2,000 Heart
SCORE participants. Black and white participants were included in the sample for statistical
analysis. All statistical analyses were conducted using Statistical Analysis System software
version 9.4 (Citation).
Variable normality was assessed prior to baseline analysis of the baseline characteristics.
Normality constraints included skewness and kurtosis that were less 2.0. All baseline variables
met the assumptions of normality with the exception of triglycerides and high-sensitivity Creactive protein. Baseline characteristics of cardiac rick factors of Black and White participants
were compared using chi-squared tests for categorical variables and student’s t test or Wilcoxon
Rank Sum Test for continuous variables. Variables that failed to meet the assumption of
normality were log-transformed to approximate normal distribution prior to the application of the
t-test.
Participant Characteristics
The overall mean age of the study participants was 59 ± 7.50. The mean age of white
men was 60 ± 7.68 and white women was 59 ± 7.24. The mean age of black men was 58 ± 7.3
and black women was 57 ± 7.64, consistent with the overall mean. White participants were
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overall nominally older and more educated than black participants. Having had some college
(less than a formal degree) was most prevalent among black participants (43%) as well the total
sample of participants. Having earned an advanced degree was most prevalent among white
participants (32.2%) and was the second most prevalent amount of education for the entire
sample (see Table 5). Overall, income was higher among white Heart SCORE participants
compared to black participants in Heart SCORE.
Participant Cardiovascular Risk Factors
According to table 4.2, hypertension (Stage I and II) was more prevalent among black
participants (56.1%) compared to white participants (38.4%). Hypertension was the most
prevalent among black men (61.3%) and black women (53.3.3%) compared to white men
(43.3%) and women (35.5%). Overall the men (60.3%) in Heart SCORE were more hypertensive
than the women (38.5). A BMI greater than 30 was more prevalent in black females (59.2%)
compared to white females (30.2%). Being overweight and/or obese was also most prevalent
among black women (59.2%) and black men (50.1%)
Only 214 of 1,944 participants (11.0%) responded that they currently smoked. Smoking
was more prevalent among blacks (55.7%) compared to whites (38.4%) and was most prevalent
among black females. (8.6%). However, more men (60.3%) were current smokers. According to
the data collected in Heart SCORE, blacks had a greater prevalence of the cardiovascular risk
factors of hypertension, being overweight and/or obese, and smoking.
Variables meeting the assumptions of normality were compared by race and gender with
application of the chi-squared tests for categorical variables and student’s t-test for continuous
variables. The Wilcoxon Rank Sum Test was applied to the variables high-sensitivity C-reactive
protein and triglycerides that violated the assumptions of normality.
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Table 5. Heart SCORE Participant Basic Demographic Information

Variable

n

Sex
Male
Female

1949

Age
45 to 55 years
56 to 65 years
Over 65 years

1949

Education
< HS
HS diploma
Some college
Bachelor’s degree
Advanced degree

1949

Marital status
Married (LiveLike)
Separated
Divorced
Widowed
Never married

1949

Employment status
Full-time
Part-time
Retired
Other

1949

Income
< $10,000
$10,000 – < $20,000
$20,000 – < $40,000
$40,000 – < $80,000
$80,000+

1761

Black

White

(% total)

(% total)

261(30.6)
593(69.4)

408(37.3)
687(62.7)

358(41.9)
324(37.9)
172(20.2)

341(31.1)
485(44.3)
269(24.6)

27(3.2)
154(18)
367(43)
160(18.7)
145(17)

17(1.6)
172(15.7)
274(25)
275(25.1)
353(32.2)

369(43.2)
51(6)
236(27.6)
89(10.4)
96(11.2)

817(74.6)
6(0.5)
136(12.4)
62(5.7)
69(6.3)

398(46.7)
87 (10.2)
305(27)
137(16.1)

469(43)
199(18.2)
230(28)
118(10.8)

79(10)
145(18.4)
257(32.7)
247(31.4)
59(7.5)

29(3)
71(7.3)
248(25.5)
338(34.7)
288(29.6)

Note. HS=high school; Live Like= living like you were married; < = Less Than.
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Table 6. Prevalence of Cardiovascular Risk Factors by Race and Gender
White n (%)
N

Black n (%)

Male

Female

Male

Female

18(6.9)
83(31.8)
110(42.1)
50(19.2)

105(17.7)
172(29)
207(34.9)
109(18.4)

77(18.9)
154(37.8)
143(35)
34(8.3)

178(25.9)
265(38.6)
180(26.2)
64(9.3)

32(12.4)
97(37.6)
76(29.5)
35(13.6)
18(7)

57(9.7)
182(31.1)
169(28.8)
99(16.9)
79(13.5)

63(15.8)
198(49.5)
89(22.3)
40(10)
10(2.5)

219(32)
258(37.7)
109(15.9)
69(10.1)
29(4.2)

B/P Classification
Normal
Prehypertension
HTN Stage I
HTN Stage II

1917

BMI
< 25
25–30
30–35
35–40
40+

1949

Current Smoker

1944

38(48.1)

51(37.5)

52(39.5)

73(12.4)

Hx Hyperlipid

1919

90(34.7)

258(44.1)

202(50.3)

326(48.3)

Hx Diabetes

1939

43(16.5)

96(16.2)

27(6.7)

33(4.8)

Hx HTN

1946

156(59.8)

328(55.4)

126(30.9)

216(31.5)

Family Hx Female
CAD

1865

57(23.6)

165(29.5)

47(11.7)

126(19.1)

Family Hx Male
CAD

1837

51(21.3)

120(21.9)

86(21.8)

171(26.1)

Note. B/P = blood pressure; HTN = hypertension; BMI = body mass index; Hyperlipid = hyperlipidemia; HX =
history; CAD = coronary artery disease.
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Table 7. t test and Wilcoxon Rank Sum Test of Cardiovascular Risk Factors (M ± SD)
Male
n

Black

White

Black

White

1943
1928
1905
1947
1947
1949
1937
1931
1382
739
581
1955
1729

58.49(7.30)
30.86(5.80)
63.86(11.12)
143.81(18.85)
85.56(11.17)
195.01(41.70)
131.90(37.56)
50.84(12.31)
1.80(.54)
.89(.18)
.92(.37)
116.04(71.66)
3.36 (8.32)

60.12(7.68)
29.36(5.47)
60.45(9.76)
134.96(17.30)
80.45(9.42)
202.9(38.02)
138.10(32.27)
49.87 (12.01)
2.11(.58)
.84(.17)
.93(.33)
136.48(80.84)
1.94(3.97)

57.99(7.64)**
32.52(6.77)**
64.90(10.64)**
140.0(20.62)**
82.11(9.88)**
214.90(44.22)*
142.70(38.98)*
61.40(14.28)
1.97(.66)**
. 81(.16)*
.89(.32)
106.21(55.49)**
4.64(8.25)**

59.50(7.24)**
28.28(5.90)**
64.50(9.94)**
132.38(19.43)**
78.27(10.12)**
224.40(41.25)*
147.90(34.98)*
61.50(15.47)
2.18(.73)**
.77(.14)*
.91(.39)
132.71(85.79)**
2.69(4.30)**

Factor
Age
BMI
Heart rate
Systolic
Diastolic
TC
LDL
HDL
PAT
CIMT
VV
Trigl
Hs-CRP

Female

Note. TC = total cholesterol; LDL = low-density lipoprotein; HDL = high-density lipoprotein; PAT = peripheral
arterial tonometry; CIMT = carotid intima media thickness; VV = vasa vasorum; Trigl = triglycerides; HsCRP=
high-sensitivity C-reactive protein.
*p < .05. *p < .001.
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The overall mean age of the study population was 59 ± 7.5. White men and white women
were nominally older (about 2 years) compared to black men (t(667) = 2.74, p < .006) and black
women (t(1278) = 3.61, p < .001), respectively. White men and women, as well as black men
and women, had on overall mean BMI indicative of being overweight or obese according to the
standards set by the World Health Organization. The mean BMI of black men and black women
was significantly higher compared to those of white men (t(656) = -3.34, p < .001) and white
women (t(1170) = -11.80, p < .001).
The findings of the non-traditional cardiovascular risk factors of high-sensitivity Creactive protein (HsCRP), carotid intima media thickness (CIMT), peripheral arterial tonometry
(PAT), and vasa vasorum (VV) generally indicated overall higher risk for blacks as compared to
whites. The mean Hs-CRP level was highest among black females and was significantly higher
compared to the mean Hs-CRP level of white females women (Z = 6.37, p < .001). Black men
also had significantly higher Hs-CRP levels compared to white men (Z = 3.75, p < .001).
Similarly, black men and women had higher mean values of carotid intima media thickness
compared to white men (t(273) = -2.03, p = 0.04) and white women (t(462) = -2.88, p = .004). In
addition, white men and white women had higher (better) mean peripheral arterial tonometry
values (a measure of endothelial function) compared to black men (t(523) = 5.87, p < .001) and
black women (t(834.99) = 4.40, p < .001). These findings indicate that for non-traditional CVD
risk factors, both black men and black females tended to present with less favorable values
compared to white men and white females.
Participant Cardiovascular Events
According to Table 8, the participants experienced a total of 158 cardiovascular events
using the composite endpoint of death/MI/AIS/stroke/PCI/CABG. Blacks had a greater incidence
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of death or MI (6.3%) compared to whites (3.5%). There were no cardiovascular events in which
white males had the lowest incidence. There was no cardiovascular event in which white females
had the highest rate of incidence. More blacks (9.7%) experienced the cardiovascular events of
death, myocardial infarction, acute ischemic stroke, stroke, percutaneous coronary intervention
or coronary artery bypass graft than whites (6.8%). Black males (16%) had the highest overall
prevalence and white females (3.9%) the lowest. Men in Heart SCORE (13.4%) had more than
two times the incidence of this cardiovascular event composite compared to women (5.3%).
Table 8. Heart SCORE Cardiovascular Events by Race and Gender
Black
Factor
Death
MI
Stroke
AIS
PCI
CABG
PCI or CABG
Death or MI
Death, MI, or AIS
Death, MI, or Stroke
Death, MI, PCI, or CABG
Death, MI, AIS, Stroke,
PCI or CABG

White

Male
(n = 261)

Female
(n = 593)

Male
(n = 408)

Female
(n = 687)

26(10)
5(1.9)
4(1.5)
3(1.1)
7(2.6)
4(1.5)
11(4.2)
29(11.1)
36(13.7)
33 (12.6)
38(14.5)
42(16.0)

18(3)
8(1.3)
7(1.1)
5(0.8)
12(2.0)
4(0.6)
14(2.3)
25(4.2)
34(5.7)
30(5.0)
35(5.6)
41(6.9)

22(5.4)
7(1.7)
8(1.9)
6(1.4)
14(3.4)
5(1.2)
19(4.6)
29(7.1)
40(9.8)
36(8.8)
42(10.2)
48(11.7)

10(1.5)
0
5(0.7)
4(0.5)
10(1.4)
2(0.2)
12(1.7)
10(1.4)
19(2.7)
15(2.1)
22(3.2)
27(3.9)

Note. Total n = 1605; MI = myocardial infarction; AIS = acute ischemic stroke; PCI = percutaneous coronary
intervention; CABG = coronary artery bypass graft.

Research Aims
Specific Aim 1
Examine the overall predictive utility of the Framingham Cardiovascular Risk Score,
Reynolds Risk Score for Women, Reynolds Risk Score for Men and the Pooled Cohort Risk
Equations using methods of calibration and discrimination.
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Cardiovascular risk scores. The Heart SCORE participants with a history of diabetes
(n=393) were excluded from analysis and did not receive a Framingham Risk Score, Reynolds
Risk Score or a Pooled Cohort Risk Score. According to the Reynolds Risk Score algorithm, a
Hemoglobin A1C (glycated hemoglobin test) blood level was required to calculate a Reynolds
Risk Score for diabetic men and women. The Heart SCORE study was a community based
research study. Therefore, a finger stick method was used to determine current blood glucose
levels, as opposed to measurement of an actual Hemoglobin A1C level, which determines the
average blood glucose level over a 2 to 3 month time period. Thus, non-diabetic Heart SCORE
participants (n=1,605) with data on cardiovascular risk factors (age, total cholesterol, highdensity lipoprotein, systolic blood pressure, treatment or no treatment of hypertension, smoking
status, family history, and high-sensitivity C-reactive protein) required for calculating the three
risk scores were included in the analyses.
Table 9. Heart SCORE Non-Diabetic Mean Cardiovascular Risk Scores of the Reynolds Risk
Score, Framingham Risk Score, and Pooled Risk Score by Race and Gender
RRS
Overall
Black men
White men
Black women
White women

FRS

Pooled

N

M

SD

M

SD

M

SD

1597
190
352
447
608

6.70
11.97
11.31
4.58
3.94

7.20
8.29
8.58
5.27
4.50

13.65
21.35
19.61
11.03
9.74

9.84
11.29
11.11
7.51
6.51

9.07
14.31
12.45
8.84
5.65

7.53
7.26
8.37
7.20
5.20

Note. RRS = Reynolds risk score; FRS = Framingham risk score; Pooled = pooled cohort risk equation.

Among all Heart SCORE participants, the mean predicted cardiovascular risk score
calculated by the Framingham Risk Score (13.65) was much higher than the corresponding mean
risk scores derived from the Reynolds Risk Score (6.7) or the Pooled Cohort Risk Score (9.07)
(Table 9). The Framingham Risk Score predicted higher 10-year risk of CVD across all
subgroups including blacks (M = 14.11, SD = 9.99), whites (M = 13.35, SD = 9.73), males (M =
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20.22, SD = 11.19), and females (M = 13.65, SD = 9.84). The corresponding Pooled Cohort Risk
Scores for blacks was (M = 10.47, SD = 7.63) and for whites was (M = 8.14, SD = 7.3).
Table 10. Heart SCORE Non-Diabetic Mean Ratio of Cardiovascular Risk Scores of the
Reynolds Risk Score, Framingham Risk Score, and Pooled Risk Score by Race and Gender

Overall
Black Men
White Men
Black women
White women

RRS/FRS

CI 95%

RRS/Pooled

CI 95%

Pool FRS

CI 95%

.44
.54
.54
.34
.34

.43, .45
.51, .57
.52, .56
.33, .36
.33, .36

.74
.82
.92
.51
.71

.73, .76
.78, .87
.89, .95
.49, .54
.69, .73

.63
.68
.60
.71
.53

.62, .64
.65, .72
.58, .62
.69, .73
.51, .55

Note. n=1597. RRS = Reynolds risk score; FRS=Framingham risk score; Pooled Score = pooled cohort risk
equation; CI = confidence interval.

The Reynolds Risk Score predicted the lowest cardiovascular risk for blacks (M= 6.78,
SD = 7.16) compared to whites (M = 6.64, SD = 7.23). Consistent with the Framingham Risk
Score and Reynolds Risk Score the Pooled Risk Score had a higher predicted mean risk for men
(M = 13.10, SD = 8.04) than women (M = 7.00, SD = 6.32). The Reynolds Risk Score had the
lowest predicted risk for males (M=11.54, SD = 8.48) and females (M= 4.21, SD = 4.85).
Thus, the three cardiovascular risk scores generated varied cardiovascular risk prediction.
The Framingham Risk Score assigned all black and white Heart SCORE participants with the
highest cardiovascular risk of the three cardiovascular risk scores. The Reynolds Risk Score
assigned the lowest cardiovascular risk to the Heart SCORE participants, which, on average, was
roughly half the value of the Framingham Risk Score (table 4.6). Using the Framingham Risk
Score as the comparison metric (the denominator), risk scores ratios across race and gender
subgroups for the Reynolds Risk Score ranged from 0.34 to 0.54. Corresponding risk score ratios
across race and gender subgroups for the Pooled Risk Score ranged from 0.53 to 0.71 (table 4.6).
Thus, in terms of absolute risk prediction of future CVD, rates were highest for the Framingham
Risk Score, intermediate for the Pooled Risk Score, and lowest for the Reynolds Risk Score.
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Specific Aim 2
Examine the overall predictive utility by race of the Framingham Cardiovascular Risk
Score, Reynolds Risk Score for Women, Reynolds Risk Score for Men, and the Pooled Cohort
Risk Equations using methods of calibration and discrimination.
Discrimination and calibration. The Heart SCORE sample (n = 1768) was used to
assess discrimination and calibration of the Framingham Risk Score, Reynolds Risk Score for
Women, Reynolds Risk Score for Men, and the Pooled Cohort Risk Equations. It was optimal to
use all the available data for this portion of the analysis. Diabetic participants are historically at
higher risk according to the cardiovascular risk models, and therefore, most likely to experience
a cardiovascular event. Therefore, inclusion of diabetic participants was optimal for accurate
assessment of discrimination and calibration of the cardiovascular risk scores. The
cardiovascular events used in the analyses (as a composite endpoint) were the occurrence of a
death, myocardial infarction (MI), stroke, Acute Ischemic Stroke (AIS), or revascularization
(coronary artery bypass grafting or percutaneous coronary intervention).
Discrimination analysis. The ability of the cardiovascular risk scores to discriminate
between individuals who will and will not experience a cardiovascular event was assessed. In
concept, a cardiovascular risk score should assign higher predicted risk scores to individuals who
subsequently experience the outcome of interest, meaning the composite endpoint of death,
myocardial infarction (MI), stroke, Acute Ischemic Stroke (AIS), or revascularization (coronary
artery bypass grafting or percutaneous coronary intervention in the present study. Likewise,
lower cardiovascular risk scores should be assigned to individuals who do not experience a
cardiovascular event. The results of the Wilcoxon Rank Sum Test conducted to determine
statistical significance of discrimination ability of the three cardiovascular risk scores overall and
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by race and gender are presented in tables 4.7, 4.8 and 4.9. Additionally, discrimination was
visually assessed with the box plots of the Wilcoxon Rank Sum tests of the Framingham Risk
Score (see figures 1 - 5), Reynolds Risk Scores for women (see figures 6 - 10), and Pooled
Cohort Risk Equations (see figures 11 - 15). Overall, the three cardiovascular risk scores
demonstrated strong evidence of being able to discriminate between individuals who ultimately
did and did not experience a cardiovascular event (see Tables 11–13) and by race and gender.
Table 11. Mean Framingham Risk Scores for Heart SCORE Participants Who Did and Did Not
Experience the Composite Cardiovascular Event of MI, Death, Stroke, AIS, or Revascularization
n

M

SD

Mdn

5%

95%

p

Overall
No
Yes

1768
154

14.54
24.31

10.77
14.22

11.65
21.02

3.37
6.25

36.77
54.56

<.0001

Black male
No
Yes

213
41

22.59
30.80

12.43
15.67

20.16
29.10

7.57
10.06

46.60
61.23

.0003

White male
No
Yes

356
47

20.07
26.24

12.28
10.84

16.88
25.02

6.55
11.56

46.80
45.48

<.0001

Black female
No
Yes

544
40

12.81
21.49

9.15
15.55

10.07
19.21

2.89
5.27

31.32
49.89

<.0001

White female
No
Yes

655
26

10.34
14.96

7.37
8.52

8.26
12.76

2.95
4.68

24.37
30.83

.001

As depicted in figure 1 and listed in table 4.7, the FRS showed strong capacity to
discriminate between participants who did and did not experience the primary composite
cardiovascular outcome (death, myocardial infarction (MI), stroke, percutaneous coronary
intervention (PCI), or coronary bypass grafting (CABG) (p < .0001). The median value was
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14.51 for participants who did not experience the CVD composite outcome versus a median
value of 24.31 for those who did.

Figure 1. Distribution of Framingham risk scores for participants who did or did not experience
the primary composite cardiovascular outcome.

Figure 2. Distribution of Framingham risk scores for Black male participants who did or did not
experience the primary composite cardiovascular outcome.
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In comparison to the overall results for the FRS, the discrimination results were similar
among black men (Figure 2, p = .0003). The median value was 22.59 for participants who did
not experience the CVD composite outcome versus a median value of 30.80 for those who did.

Figure 3. Distribution of Framingham risk scores for White male participants who did or did not
experience the primary composite cardiovascular outcome.
When compared to the overall results for the FRS, the discrimination results were similar
among white men (Figure 3, p < .0001). The median value was 20.07 for participants who did
not experience the CVD composite outcome versus a median value of 26.24 for those who did.
In comparison to the overall results for the FRS and results for men, the discrimination
results were similar among black females (Figure 4, p < .0001). The median value was 12.81 for
participants who did not experience the CVD composite outcome versus a median value of 21.49
for those who did.
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Figure 4. Distribution of Framingham risk scores for Black female participants who did or did
not experience the primary composite cardiovascular outcome.

Figure 5. Distribution of Framingham risk scores for White female participants who did or did
not experience the primary composite cardiovascular outcome.
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In comparison to the overall results for the FRS and results for men and black females,
the discrimination results were similar among white females (Figure 4, p = .0007). The median
value was 10.34 for participants who did not experience the CVD composite outcome versus a
median value of 14.96 for those who did.
Table 12. Reynolds Risk Scores for Heart SCORE participants with and without the
cardiovascular event of MI, Death, Stroke, AIS, or Revascularization
n

M

SD

Mdn

5%

95%

p

Overall
No
Yes

1508
108

6.26
13.02

6.88
8.84

3.95
10.93

.62
1.41

19.05
26.73

<.0001

Black male
No
Yes

169
25

11.27
15.84

8.02
8.78

9.62
13.76

2.81
5.30

25.25
26.54

.002

White male
No
Yes

317
39

10.81
16.07

8.54
8.10

8.08
16.79

2.22
4.69

29.81
29.41

<.0001

Black female
No
Yes

428
25

4.74
10.26

2.71
9.36

8.03
7.14

0.48
1.34

12.96
32.78

<.0001

White female
No
Yes

594
19

3.88
6.68

4.50
4.78

2.53
5.25

0.54
0.85

11.34
15.07

.002

As depicted in figure 6 and listed in table 4.8, the RRS showed strong capacity to
discriminate between participants who did and did not experience the primary composite
cardiovascular outcome (death, myocardial infarction (MI), stroke, percutaneous coronary
intervention (PCI) or coronary bypass grafting (CABG) (p < .0001). The median value was 6.26
for participants who did not experience the CVD composite outcome versus a median value of
13.02 for those who did.
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Figure 6. Distribution of Reynolds risk score participants who did or did not experience the
primary composite cardiovascular outcome.

Figure 7. Distribution of Reynolds risk score Black male participants who did or did not
experience the primary composite cardiovascular outcome.
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In comparison to the overall results for the RRS, the discrimination results were similar
among black men (Figure 7, p = .002). The median value was 11.27 for participants who did not
experience the CVD composite outcome versus a median value of 15.84 for those who did.

Figure 8. Distribution of Reynolds risk score White male participants who did or did not
experience the primary composite cardiovascular outcome.
When compared to the overall results for the RRS, the discrimination results were similar
among white men (Figure 8, p < .0001). The median value was 10.81 for participants who did
not experience the CVD composite outcome versus a median value of 16.07 for those who did.
In comparison to the overall results for the RRS and results for men, the discrimination
results were similar among black females (Figure 9, p < .0001). The median value was 4.74 for
participants who did not experience the CVD composite outcome versus a median value of 10.26
for those who did.
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Figure 9. Distribution of Reynolds risk score Black female participants who did or did not
experience the primary composite cardiovascular outcome.

Figure 10. Distribution of Reynolds risk score White female participants who did or did not
experience the primary composite cardiovascular outcome.
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In comparison to the overall results for the RRS and results for men and black females,
the discrimination results were similar among white females (Figure 10, p = .0014). The median
value was 3.88 for participants who did not experience the CVD composite outcome versus a
median value of 6.68 for those who did.
Table 13. Pooled Cohort Risk Equation Scores for Heart SCORE participants with and without
the cardiovascular event of MI, Death, Stroke, AIS, or Revascularization
n

M

SD

Mdn

5%

95%

p

Overall
No
Yes

1794
154

10.03
18.70

8.93
12.62

7.49
15.76

1.08
3.07

28.54
43.86

<.0001
<.0001

Black male
No
Yes

209
41

15.85
22.95

9.04
12.64

13.55
21.68

5.19
7.03

33.20
47.70

.0002

White male
No
Yes

356
47

12.89
18.72

9.60
9.58

10.11
16.24

2.78
6.24

45.43
35.77

<.0001

Black female
No
Yes

544
40

10.71
20.18

9.35
15.53

8.03
17.50

0.89
2.87

29.24
42.50

<.0001

White female
No
Yes

655
26

6.06
9.65

5.92
7.43

3.99
7.98

0.92
1.52

18.02
26.03

.003

As depicted in figure 11 and listed in table 4.9, the Pooled Cohort Risk Equations showed
strong capacity to discriminate between participants who did and did not experience the primary
composite cardiovascular outcome (death, myocardial infarction (MI), stroke, percutaneous
coronary intervention (PCI) or coronary bypass grafting (CABG) (p < .0001). The median value
was 10.03 for participants who did not experience the CVD composite outcome versus a median
value of 18.70 for those who did.
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Figure 11. Distribution of pooled cohort risk equation participants who did or did not experience
the primary composite cardiovascular outcome.

Figure 12. Distribution of pooled cohort risk equation Black male participants who did or did
not experience the primary composite cardiovascular outcome.
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In comparison to the overall results for the Pooled Cohort Risk Equations, the
discrimination results were similar among black men (Figure 12 p = .0002). The median value
was 15.85 for participants who did not experience the CVD composite outcome versus a median
value of 22.95 for those who did.

Figure 13. Distribution of pooled cohort risk equation White male participants who did or did
not experience the primary composite cardiovascular outcome.
When compared to the overall results for the Pooled Cohort Risk Equations, the
discrimination results were similar among white men (Figure 13, p < .0001). The median value
was 12.89 for participants who did not experience the CVD composite outcome versus a median
value of 18.72 for those who did.
In comparison to the overall results for the Pooled Cohort Risk Equations and results for
men, the discrimination results were similar among black females (Figure 14, p < .0001). The
median value was 10.71 for participants who did not experience the CVD composite outcome
versus a median value of 20.18 for those who did.
98

Figure 14. Distribution of pooled cohort risk equation Black female participants who did or did
not experience the primary composite cardiovascular outcome.

Figure 15. Distribution of pooled cohort risk equation White female participants who did or did
not experience the primary composite cardiovascular outcome.
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In comparison to the overall results for the Pooled Cohort Risk Equations and results for
men, the discrimination results were similar among white females (Figure 15, p = .0015). The
median value was 6.06 for participants who did not experience the CVD composite outcome
versus a median value of 9.65 for those who did.
Thus, in summary, all 3 risk scores demonstrated strong evidence of being able to
discriminate among individuals who ultimately did and did not experience the CVD composite
outcome of interest. This occurred across gender and race subgroups, and irrespective of the fact
that absolute predicted rates of CVD varied substantially across the three risk scores.
Calibration analysis. The predicted risk scores of the Framingham Heart Score,
Reynolds Risk Score, and Pooled Cohort Risk Equations) were divided into quintiles. The mean
predicted risk score was calculated for each quintile. The cardiovascular risk scores of the
individuals who experienced the composite cardiovascular event of interest were divided into
quintiles for each of the cardiovascular risk scores. The mean observed risk score was calculated
for each quintile. The calibration of the Framingham Risk Score (see figures 16- 20), Reynolds
Risk Score (see figures 21 - 25), and Pooled Cohort Risk Equations (see figures 26 - 30) were
assessed. Specifically, the degree of concordance among the mean predicted risk scores and
mean observed risk scores for the quintiles for each cardiovascular risk score was assessed.
As depicted in figures 16 - 20, the Framingham risk score consistently overestimated the
10-year risk of a cardiovascular event across race and gender. Ten year cardiovascular risk was
consistently overestimated across the low, intermediate and high quintiles of risk as compared to
the observed risk. Thus, the Framingham Risk score demonstrated relatively poor precision in
predicting 10-year cardiovascular risk scores across race and gender. The 10-year predicted
cardiovascular risk predictions from the Reynolds Risk Scores demonstrated markedly better
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precision when compared to the observed cardiovascular risk overall and across race and gender.
Indeed, there was remarkable consistency among predicted vs. observed rates of CVD in white
males. In black males, risk was slightly under predicted at the higher risk quintile as well as one
of the lower risk quintiles. Ten year cardiovascular risk was also under predicted in the higher
quintile of risk in black females and over predicted in white females. Risk was also under
predicted in the lowest quintiles of risk in black females. Overall there was variation in the
accuracy of risk prediction in the lower quintiles of cardiovascular risk. However, in aggregate,
the Reynolds Risk Scores appeared to predict future CVD risk with reasonable precision by both
gender and race. Overall, the Pooled Cohort Risk Equations overestimated 10-year risk of a
cardiovascular event across race and gender (see figures 26 - 30). This degree of overestimation
was lower than that of the Framingham Risk Score (previous figures 16-20). For black females
and white females, the Pooled Cohort Risk Equation over estimated risk in higher risk quintiles.
Risk was underestimated in the intermediate risk quintile for black and white males. Predicted
10-year cardiovascular risk was inconsistent in the lower risk quintiles. Interestingly, predicted
10-year cardiovascular risk was overestimated for white males in the low risk quintiles. Thus,
results for the Pooled Cohort Risk Equations indicated marginal precision across quintiles.
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Figure 16. Framingham risk score overall predicted risk and observed risk for the primary
composite cardiovascular outcome.
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Figure 17. Framingham risk score predicted risk and observed risk for the primary composite
cardiovascular outcome in Black males.
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Figure 18. Framingham risk score predicted risk and observed risk for the primary composite
cardiovascular outcome in White males.
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Figure 19. Framingham risk score predicted risk and observed risk for the primary composite
cardiovascular outcome in Black females.
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Figure 20. Framingham risk score predicted risk and observed risk for the primary composite
cardiovascular outcome in White females.
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Figure 21. Reynolds risk score overall predicted risk and observed risk for the primary
composite cardiovascular outcome.
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Figure 22. Reynolds risk score predicted risk and observed risk for the primary composite
cardiovascular outcome in Black males.
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Figure 23. Reynolds risk score predicted risk and observed risk for the primary composite
cardiovascular outcome in White males.
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Figure 24. Reynolds risk score predicted risk and observed risk for the primary composite
cardiovascular outcome in Black females.
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Figure 25. Reynolds risk score predicted risk and observed risk for the primary composite
cardiovascular outcome in White females.
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Figure 26. Pooled cohort risk equations overall predicted risk and observed risk for the primary
composite cardiovascular outcome.
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Figure 27. Pooled cohort risk equations predicted risk and observed risk for the primary
composite cardiovascular outcome in Black males.
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Figure 28. Pooled cohort risk equations predicted risk and observed risk for the primary
composite cardiovascular outcome in White males.
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Figure 29. Pooled cohort risk equations predicted risk and observed risk for the primary
composite cardiovascular outcome in Black females.
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Figure 30. Pooled cohort risk equations predicted risk and observed risk for the primary
composite cardiovascular outcome in White females.
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Specific Aim 3
Assess the predictive utility of the Framingham cardiovascular risk score, Reynolds Risk
Score for women, Reynolds Risk Score for Men and the Pooled Cohort Risk Equations with the
inclusion of the variables carotid intima media thickness (CIMT), pulse amplitude tonometry
(PAT), and/or vasa vasorum (VV).
Table 14. Cox Regression Analysis of the Framingham Risk Score, Reynolds Risk Scores, and
Pooled Cohort Risk Scores by Race and Gender in Heart SCORE
Risk Score

n

HR

95% CI

AIC

p

Overall
Framingham
Reynolds risk
Pooled

1922
1616
1918

1.27
1.40
1.35

[1.22, 1.33]
[1.30, 1.50]
[1.28, 1.42]

2177.92
1497.03
2166.71

<.0001
<. 0001
<. 0001

Black Males
Framingham
Reynolds risk
Pooled

254
194
250

1.19
1.24
1.30

[1.08, 1.30]
[1.04, 1.47]
[1.15, 1.46]

414.067
246.59
409.36

.0002
.01
<. 0001

White Males
Framingham
Reynolds risk
Pooled

403
356
403

1.16
1.26
1.25

[1.06, 1.27]
[1.11, 1.43]
[1.12, 1.41]

534.63
434.17
530.69

.001
.0003
<. 0001

Black Females
Framingham
Reynolds risk
Pooled

584
453
584

1.31
1.63
1.32

[1.20, 1.43]
[1.36, 1.95]
[1.21, 1.43]

470.87
278.28
468.46

<. 0001
<. 0001
<. 0001

White Females
Framingham
Reynolds risk
Pooled

681
613
681

1.33
1.42
1.36

[1.13, 1.58]
[1.12, 1.81]
[1.13, 1.64]

325.72
235.62
326.86

<. 0001
.003
.0008

Note. HR = hazard ratio; CI = confidence interval; AIC = Akiake information criteria, Framingham= Framingham
risk score; Reynolds Risk = Reynolds risk score; Pooled = Pooled cohort risk equation.

Without consideration of any of the novel risk factors, and based on the total population,
table 4.10 provides hazard ratio estimates for the three risk scores in relation to future
cardiovascular risk. Overall, hazard ratio estimates ranged from a low of 1.27 for Framingham
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Risk Score to a high of 1.40 for the Reynolds Risk Score. Moreover, the AIC value was lowest
(best) for the Reynolds Risk Score in terms of assessment of model fit. Similar results were
observed by race and gender.
Table 15. Framingham Risk Scores, Reynolds Risk Scores, Pooled Cohort Risk Scores with
inclusion of novel risk factors of PAT, CIMT, or VV for Heart SCORE participants
Model

n

HR

95% CI

AIC

p

1. Framingham
2. FRS + PAT
PAT
1. Framingham
2. FRS + CIMT
CIMT
1. Framingham
2. FRS + VV
VV

1396

1.25
1.24
0.89
1.34
1.33
1.38
1.38
1.38
1.72

[1.18, 1.32]
[1.17, 1.32]
[0.69, 1.51]
[1.22, 1.47]
[1.20, 1.47]
[0.27, 6.94]
[1.23, 1.54]
[1.23, 1.54]
[.81, 3.67]

1516.06
1517.56

<. 0001
<. 0001
.48
<. 0001
<. 0001
.69
<. 0001
<. 0001
.15

1. Reynolds Risk
2. RRS + PAT
PAT
1. Reynolds Risk
2. RRS + CIMT
CIMT
1. Reynolds Risk
2. RRS + VV
VV

1156

1.39
1.39
0.76
1.39
1.29
6.91
1.47
1.47
0.93

[1.28, 1.51]
[1.28, 1.52]
[0.52, 1.11]
[1.20, 1.61]
[1.09, 1.52]
[1.08, 44.1]
[1.25, 1.72]
[1.25, 1.72]
[0.29, 2.97]

1091.14
1091.06

1. Pooled Risk
2. PRS+ PAT
PAT
1. Pooled Risk
2. PRS + CIMT
CIMT
1. Pooled Risk
2. PRS + VV
VV

1366

1.31
1.31
0.88
1.51
1.49
1.76
1.55
1.54
1.71

[1.22, 1.40]
[1.19, 1.45]
[0.65, 1.18]
[1.35, 1.68]
[1.33, 1.67]
[0.35, 8.74]
[1.35, 1.78]
[1.34, 1.77]
[0.75, 3.92]

1514.49
1515.78

733
576

638
498

732
575

554.23
556.08
392.19
392.47

383.02
381.00
258.46
260.45

543.34
544.87
386.21
386.75

<. 0001
<. 0001
.16
.0001
.003
.04*
<. 0001
<. 0001
.91
<. 0001
<. 0001
.40
<. 0001
<. 0001
.48
<. 0001
<. 0001
.20

Note. HR = hazard ratio; CI = confidence interval; AIC = Akiake information criteria; FRS = Framingham risk
score; PAT = peripheral arterial tonometry; CIMT = carotid intima media thickness; VV = vasa vassorum; RRS =
Reynolds risk score; PRS = Pooled cohort risk equation.
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The hazard ratios for the three risk scores are presented in tables 4.11 (including addition
of novel risk factors), and based on the participants with the risk factors to compute all three
cardiovascular risk scores. As seen, the hazard ratios range from a low of 1.25 for the
Framingham Risk Score to a high of 1.39 for the Reynolds Risk Score (p < 0.0001 for all risk
scores). In nested models that added either peripheral arterial tonometry (PAT), carotid artery
intima media thickness (CIMT), or vasa vasorum (VV), the risk score estimates were only
nominally attenuated. This is further reflected in nearly identical AIC values for the index model
and addition of novel risk factors. An exception was the Reynolds Risk Score model where
CIMT was independently associated with future cardiovascular risk (HR = 6.91, p = .04).
The hazard ratios for the three risk scores for black participants are presented in table
4.12, As seen, they range from a low of 1.26 for the Framingham Risk Score to a high of 1.64 for
the Reynolds Risk Score (p < .05 for all risk scores). In nested models that added either
peripheral arterial tonometry (PAT), carotid artery intima media thickness (CIMT), or vasa
vasorum (VV), the risk score estimates were only nominally attenuated. This is further reflected
in nearly identical AIC values for the index model and addition of novel risk factors. There was
no novel risk factor that was independently associated with future cardiovascular risk among
black participants.
The hazard ratios for the three risk scores among white participants are presented in
tables 4.13, and based on the participants with the risk factors to compute all three cardiovascular
risk scores. As seen, the hazard ratios range from a low of 1.20 for the Framingham Risk Score
to a high of 1.57 for the Pooled Cohort Risk Equations score (p < 0.05 for all risk scores). In
nested models that added either peripheral arterial tonometry (PAT), carotid artery intima media
thickness (CIMT), or vasa vasorum (VV), the risk score estimates were only nominally
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Table 16. Framingham Risk Scores, Reynolds Risk Scores, Pooled Cohort Risk Scores with
inclusion of novel risk factors of PAT, CIMT, or VV for Black Heart SCORE participants
Model

n

HR

95% CI

AIC

p

1. Framingham
2. FRS + PAT
PAT
1. Framingham
2. FRS + CIMT
CIMT
1. Framingham
2. FRS + VV
VV

557

1.26
1.26
0.82
1.48
1.48
.70
1.43
1.43
0.77

[1.16, 1.38]
[1.15, 1.37]
[.50, .32]
[1.26, 1.73]
[1.26, 1.74]
[.06, 8.35]
[1.19, 1.71]
[1.19, 1.72]
[.15, 3.98]

622.79
624.08

<. 0001
<. 0001
.41
<. 0001
<. 0001
.78
.0001
.0001
.76

1. Reynolds Risk
2. RRS + PAT
PAT
1. Reynolds Risk
2. RRS + CIMT
CIMT
1. Reynolds Risk
2. RRS + VV
VV

427

1.51
1.51
0.75
1.63
1.59
11.45
1.64
1.83
0.07

[1.30, 1.77]
[1.29, 1.77]
[.41, 1.37]
[1.25, 2.11]
[1.19, 2.12]
[.62, 209.12]
[1.20, 1.23]
[1.25, 2.67]
[.00, 3.40]

400.97
402.06

1. Pooled Risk
2. PRS+ PAT
PAT
1. Pooled Risk
2. PRS + CIMT
CIMT
1. Pooled Risk
2. PRS + VV
VV

554

1.29
1.29
0.80
1.59
1.59
1.13
1.54
1.54
0.84

[1.17, 1.43]
[1.16, 1.43]
[.49, 1.28]
[1.34, 1.88]
[1.34, .88]
[.08, 14.86]
[1.26, 1.87]
[1.26, 1.88]
[.16, 4.37]

624.42
625.50

249
201

198
160

248
200
557

195.01
196.93
137.04
138.94

104.50
104.02
70.50
65.50

189.96
191.95
133.85
135.81

<. 0001
<. 0001
.35
.0002
.001
.10
.001
.001
.18
<. 0001
<. 0001
.35
<. 0001
<. 0001
.92
<. 0001
<. 0001
.83

Note. HR = hazard ratio; CI = confidence interval; AIC = Akiake information criteria, FRS = Framingham risk
score; PAT = peripheral arterial tonometry; CIMT = carotid intima media thickness; VV = vasa vassorum; RRS =
Reynolds risk score; PRS = Pooled cohort risk equation.
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Table 17. Framingham Risk Scores, Reynolds Risk Scores, Pooled Cohort Risk Scores With
Inclusion of Novel Risk Factors of PAT, CIMT, or VV for White Heart SCORE Participants
Model

n

HR

95% CI

AIC

p

1. Framingham
2. FRS + PAT
PAT
1. Framingham
2. FRS + CIMT
CIMT
1. Framingham
2. FRS + VV
VV

812

1.20
1.24
1.02
1.29
1.25
2.68
1.35
1.36
2.19

[1.14, 1.33]
[1.14, 1.34]
[0.69, 1.51]
[1.14, 1.46]
[1.09, 1.44]
[0.31, 23.18]
[1.16, 1.56]
[1.17, 1.58]
[0.98, 4.90]

738.31
740.30

<. 0001
<. 0001
.90
<. 0001
<. 0001
.37
<. 0001
<. 0001
.05*

1. Reynolds Risk
2. RRS + PAT
PAT
1. Reynolds Risk
2. RRS + CIMT
CIMT
1. Reynolds Risk
2. RRS + VV
VV

729

1.36
1.36
.86
1.33
1.22
6.38
1.42
1.42
1.36

[1.22, 1.52]
[1.22, 1.52]
[0.54, 1.38]
[1.11, 1.61]
[0.98, 1.53]
[0.55, 73.22]
[1.18, 1.72]
[1.17, 1.72]
[0.44, 4.20]

574.22
575.84

1. Pooled Risk
2. PRS+ PAT
PAT
1. Pooled Risk
2. PRS + CIMT
CIMT
1. Pooled Risk
2. PRS + VV
VV

812

1.31
1.31
.97
1.43
1.39
3.10
1.55
1.57
2.29

[1.19, 1.45]
[1.19, 1.45]
[0.66, 1.42]
[1.23, 1.66]
[1.18, 1.64]
[0.38, 24.98]
[1.26, 1.91]
[1.26, 1.94]
[0.93, 5.64]

737.44
739.41

484
375

440
338

484
200
812

294.07
295.30
211.67
210.87

236.99
236.85
166.48
168.22

291.51
292.45
209.97
209.35

<. 0001
<. 0001
.54
.0001
.06
.13
<. 0002
.0003
.59
<. 0001
<. 0001
.87
<. 0001
<. 0001
.28
<. 0001
<. 0001
.07

Note. HR = hazard ratio; CI = confidence interval; AIC = Akiake information criteria; FRS = Framingham risk
score; PAT = peripheral arterial tonometry; CIMT = carotid intima media thickness; VV = vasa vassorum; RRS =
Reynolds risk score; PRS = Pooled cohort risk equation.
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attenuated. This is further reflected in nearly identical AIC values for the index model and
addition of novel risk factors. The exception was the Framingham Risk Score model where VV
was borderline independently associated with future cardiovascular risk (HR = 2.19, 95% CI [.98
– 4.90], p = .05). Similarly, for examination of the Pooled Cohort Risk Score, there was a
suggestion of VV being independently associated with future risk of CVD (HR = 2.29, 95% CI
[0.93 – 5.64], p = .07).
Chapter Summary
The analyses to address the three specific aims of this study yielded four main findings.
First, the overall predicted 10-year absolute risk according to the Framingham Risk Score,
Reynolds Risk Scores, and Pooled Cohort Risk Equations varied substantially across the three
measures. Second, this pattern of substantial risk variation held true across race and gender.
Third, despite large variation in estimates of absolute risk of future CVD, the cardiovascular risk
score equations were all strongly associated with future cardiovascular risk. Specifically,
individuals with low occurrence of a cardiovascular event tended to have low risk scores, and
individuals with higher occurrence of a cardiovascular event tended to have higher scores.
Lastly, despite the examination of novel risk factors to improve risk prediction, such novel risk
factors did not significantly improve 10-year cardiovascular risk prediction.
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CHAPTER 5: DISCUSSION, CONCLUSIONS, AND RECOMMENDATIONS
This final chapter includes a synthesis of the results from the study with discussion of the
findings, conclusions, and implications for nursing and future research recommendations. The
purpose of this research study was an assessment and comparison of the Framingham Risk score,
Reynolds Risk scores, and the Pooled Cohort Risk Equation scores with respect to ability to
predict cardiovascular events in a diverse ethnic population.
This research was guided by three aims:
1. Examine the overall predictive utility of the Framingham Cardiovascular Risk Score,
Reynolds Risk Score for Women, Reynolds Risk Score for Men, and the Pooled
Cohort Risk Equation using methods of discrimination and calibration.
2. Examine the overall predictive utility by race of the Framingham Cardiovascular Risk
Score, Reynolds Risk Score for Women, Reynolds Risk Score for Men, and the
Pooled Cohort Risk Equation using methods of discrimination and calibration.
3. Assess the predictive utility of the Framingham Cardiovascular Risk Score, Reynolds
Risk Score for Women, Reynolds Risk Score for Men, and the Pooled Cohort Risk
Equation with the inclusion of the variables carotid intima media thickness (CIMT),
pulse amplitude tonometry (PAT), and/or vasa vasorum (VV).
Study Summary
A secondary data analysis of data from the Heart Strategies Concentrating on Risk
Evaluation (Heart SCORE) was conducted. Heart SCORE is longitudinal prospective cohort
study conducted over a ten year time period. The demographic, clinical history, and biological
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variables were extracted from the Heart SCORE dataset. The prevalence of demographic
variables overall and by race was illustrated by percentages and means and standard deviations.
Statistical testing of the prevalence of cardiovascular risk factors by race was performed by use
of chi-square tests, t-tests, and Wilcoxon Rank Sum Tests. The occurrence of cardiovascular
events of the Heart SCORE participants were collected over the ten-year study period. Incidence
rates of cardiovascular events overall and by race and gender were calculated.
To examine the overall predictive utility of the Framingham Cardiovascular Risk Score,
Reynolds Risk Score for Women, Reynolds Risk Score for Men, and the Pooled Cohort Risk
Equation, the three risk scores were calculated using their published algorithms. The mean risk
scores for black men, black women, white men, and white women were compared. Calibration of
the cardiovascular risk scores was assessed by examining the degree of concordance among
mean predicted risk scores and mean observed risk scores. The distributions of cardiovascular
risk scores of participants who did and did not experience the composite cardiovascular endpoint
of interest (death, myocardial infarction (MI), death, stroke, Acute Ischemic Stroke (AIS), or
revascularization) were compared by use of Wilcoxon Rank Sum Tests. These analyses
examined the extent to which the three risk scores were able to discriminate future
cardiovascular risk, overall and by race and gender. The predictive utility of the Framingham
Cardiovascular risk score, Reynolds Risk Score for Women, Reynolds Risk Score for Men, and
the Pooled Cohort Risk Equation with the inclusion of the variables carotid intima media
thickness (CIMT), pulse amplitude tonometry (PAT), and/or vasa vasorum (VV) was evaluated
with the use of Cox regression modeling.
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Conclusions and Discussion
There were four main findings from this research. First, using three well-established
methods for estimating future cardiovascular risk, the overall predicted 10-year absolute risk
estimates varied substantially across the three measures. Second, this pattern of substantial risk
variation held true across race and gender. Third, despite large variations in absolute risk
predictions, the cardiovascular risk score equations were strongly associated with future
cardiovascular risk. Individuals with low occurrence of a cardiovascular event tended to have
low risk scores, and individuals with a higher occurrence of a cardiovascular event tended to
have higher scores. Lastly, despite the examination of novel risk factors to improve risk
prediction, such novel risk factors did not significantly improve 10-year cardiovascular risk
prediction.
The Framingham Risk Score, Reynolds Risk Scores, and Pooled Cohort Risk Equation
Risk Score generated highly variable overall cardiovascular risk predictions. The Framingham
Risk Score assigned all Heart SCORE participants with the highest cardiovascular risk of the
three cardiovascular risk scores. These findings are consistent with findings in the literature
(DeFilips et al., 2015; Goff et al, 2013). The Reynolds Risk Score assigned the lowest
cardiovascular risk to the Heart SCORE participants. The variation in predicted cardiovascular
risk of the Framingham Risk score and the Reynolds Risk Score for women was also consistent
with findings in the literature (DeFilipps et al., 2015; Tattersall et al., 2012). The Pooled Cohort
Risk Equation predicted a higher overall cardiovascular risk compared to the Reynolds Risk
Scores for women and men and a lower overall risk when compared to the Framingham Risk
Scores. The application of the Pooled Cohort Risk Equation indicates variation in overall
cardiovascular risk prediction when compared to the Framingham Risk Score and Reynolds Risk
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Score for women (Preis & Kristensen, 2015). Looking at the range of future cardiovascular risk
predictions form these risk scores, Framingham predictions were highest and Reynolds Risk
Score predictions were the lowest.
The substantial risk variation held true across race and gender when comparing the
cardiovascular risk scores. The ratio of mean cardiovascular risk scores indicated a largest
variation in predicted cardiovascular risk among white men (.54 - .92) and the smallest among
black men (.54 - .82). Black and white women had the same range of variation (.34 - .71), (.34.71). Predicted 10-year cardiovascular risk was dependent upon which of the three risk scores
was calculated overall and across race and gender. The substantial variation in predicted risk is a
known limitation of cardiovascular risk prediction (Goff et al, 2013; Preiss & Kristensen, 2015).
Despite large variations in absolute risk predictions, the cardiovascular risk score
equations all showed strong association with future cardiovascular risk. Individuals with the
lowest scores tended to be at the lowest risk of a cardiovascular event, and vice versa. The
Framingham Risk Score, Reynolds Risk Scores, and Pooled Cohort Risk Equations were able to
successfully discriminate among Heart SCORE participants at low or high risk for the clinically
relevant composite cardiovascular endpoint consisting of death, myocardial infarction (MI),
stroke, Acute Ischemic Stroke (AIS), or revascularization (coronary artery bypass grafting or
percutaneous coronary intervention). Additionally, the three risk scores discriminated among
white and the black Heart SCORE participants of both genders. DeFillips et al., (2015) found all
three risk scores had good discrimination across race and gender. In the findings from Ridker et
al., the Reynolds Risk Score for men and a traditional risk model (age, blood pressure, smoking,
total cholesterol, and high-density lipoprotein), which was similar to the Framingham Risk Score
discriminated well (Ridker et al., 2008). In the development of the Reynolds Risk Score for
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women, Ridker et al., (2007) found the RRS had better discrimination for women compared to
FRS. These findings are similar to the findings of discrimination in this study. In this study, the
Pooled Cohort Risk Equation was found to have adequate discrimination. However, the Pooled
Cohort Risk Equation was found to poorly discriminate in external cohorts (Munter et al., 2014).
Importantly, the statistical method of Wilcoxon Rank Sum Tests to assess discrimination of the
three risk scores in this study was not Harrell’s C-statistic, which used to assess discrimination in
the studies above. Additionally, when assessing the discrimination of these three cardiovascular
risk scores, it is important to recognize that each was developed to predict different
cardiovascular events/endpoints. Thus, at least some variation in measures of discrimination and
calibration may be expected to occur across the three risk scores.
A well-calibrated risk score assigns the correct probability of an event at all levels of
predicted risk (Royston & Altman, 2013). The ability of the three cardiovascular risk scores to
accurately predict the risk of a cardiovascular event in 10 years across the quintiles of predicted
cardiovascular risk (risk quintiles) was assessed. The risk scores evaluated portend a 10-year risk
estimate, however, the mean follow up in Heart SCORE participants was 8 years. Therefore, an
adjustment procedure was used to estimate (interpolate) 10-year risk. Calibration of the
Framingham Risk Score was consistent across race and gender. The discordance among
predicted risk and observed risk indicated overestimation of predicted risk across race and
gender. The overestimation of cardiovascular risk from Framingham risk scores was consistent
with other findings in the literature (Cook et al., 2012; DeFilips et al., 2015; Goff et al., 2013).
An overestimation of risk in non-white populations is a well-known finding in Framingham risk
score research (Goff et al., 2013; Mendis, 2010; Payne, 2012). The Reynolds Risk Scores
performed reasonably well in estimating overall 10-year predicted cardiovascular risk. The
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strongest concordance between the predicted and observed risk was in the intermediate risk
quintile. Risk was somewhat under predicted at the highest risk quintile for blacks compared to
whites. This important finding is partially consistent with previous research demonstrating poor
calibration of cardiovascular risk prediction among blacks (Goff et al., 2013). The Pooled Cohort
Risk Equations were developed to address the disparity in cardiovascular risk prediction among
black men and women. However, the findings of this study indicate overall over estimation of
risk across race and gender. Additionally, the Pooled Cohort Risk Equations under predicted risk
in black men and women at the quintile of lowest risk. Cardiovascular risk was underestimated in
the intermediate quintile of risk in black men and whites men. These findings of over prediction
are consistent with the over prediction in the cohorts used to develop the risk score and
validation cohorts (DeFilipps et al., 2015; Munter et al., 2014; Preis & Kristensen, 2015). The
findings from this study of under prediction in the lowest quintile and intermediate quintile of
risk among men indicate variation in cardiovascular prediction that may warrant further
investigation.
Despite the examination of novel risk factors to potentially improve risk prediction, novel
risk factors did not significantly improve 10-year cardiovascular risk prediction. With the minor
exception of the Reynolds Risk Score model where CIMT was independently associated with
overall future cardiovascular risk, there was little indication of any appreciable improvement in
model performance with the addition of novel risk factors. In the Framingham Risk Score model,
the association between vasa vasorum and future cardiovascular risk in white participants was
borderline and added a very small improvement in mode performance. Whereas this lack of new
information may seem discouraging, it is also not entirely unexpected. Specifically, the three risk
scores evaluated in this study are based on decades of previous research and intensive searches
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aimed at optimizing the predictive ability of the respective algorithms. The present analysis
corroborates the utility of these efforts ant the risk scores in use, and underscores the challenge in
finding novel risk factors that may appreciably improve upon these algorithms.
Implications of Findings
In summary, the purpose of this research study was to assess and compare the
Framingham Risk score, Reynolds Risk scores, and the Pooled Cohort Risk Equation scores with
respect to their ability to predict cardiovascular events in a diverse ethnic population (Heart
SCORE). Identification and measurement of cardiovascular risk is essential to beginning
treatment so as to avoid future cardiac events (Lloyd Jones, 2010). The use of cardiovascular risk
scores remains the foundation for risk stratification to guide clinical management as well as early
detection (Wachira & Stys, 2013). Clinicians have access to several cardiovascular risk scores in
practice settings. While having several risk scores with different risk factors may provide more
information, it does not imply accuracy of the cardiovascular risk score used to calculate a given
individual’s cardiovascular risk. The results of this research indicate there is a high degree of
variation among the predicted cardiovascular risk scores (despite the similarity in risk factors
used to calculate predicted risk). Moreover, the accuracy of the predicted cardiovascular risk
score may vary depending on the race and sex of the patient. The finding of discordance among
predicted 10-year cardiovascular risk and observed cardiovascular risk among the Framingham
Risk Score (in particular), Reynolds Risk Score and Pooled Cohort Risk Equations score is
consistent with the cardiovascular risk research. An additional consideration is these
discordances in cardiovascular risk scores can also be interpreted with the notion that risk
assessment of cardiovascular disease is an inexact science, and risk and outcome should be
looked at as multifactorial (Preiss & Kristensen, 2015).
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Investigation of the awareness and perception of clinicians regarding variation in
predicted cardiovascular risk from different cardiovascular risk scores is recommended.
Additionally, clinicians’ awareness and perception of the accuracy of cardiovascular risk
prediction is important as it pertains to race and gender.
For most patients under normal circumstances, it is recommended for clinicians to apply
the current guidelines (ACC/AHA) in addition to their clinical judgment and circumstances of
the individual (Preiss & Kristensen, 2015). The current guidelines recommend the Pooled Cohort
Risk Equations to predict atherosclerotic cardiovascular disease risk (Goff et al., 2013).
However, in the present, study, the Reynolds Risk Scores (for women and men) demonstrated
the best precision when compared to the observed cardiovascular risk overall and across race and
gender compared to the Framingham Risk Score and the Pooled Cohort Risk Score. Based on
this finding, the data support use of the Reynolds Risk Score in the clinical arena. Importantly,
providing the patient with their predicted 10-year cardiovascular risk according to the
Framingham Risk Score (which consistently provided higher risk estimates compared to the
Reynolds Risk Score) in conjunction with the Reynolds Risk Score will provide a range of
estimates of 10- year cardiovascular risk.
Clinical management is guided by stratified predicted cardiovascular risk in men over 55
years of age and women over 65 years of age with multiple cardiovascular risk factors (Lloyd
Jones, 2010). Cardiovascular risk scores stratifiy ounger adults under the age of 45 as having a
lower cardiovascular risk due to overall less cardiovascular risk burden. The inclusion of young
adult participants in cardiovascular risk research may provide more knowledge on the predicted
risk of individuals stratified at lower or intermediate risk, as well as the accuracy of
cardiovascular risk score used to predict risk.
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As indicated by previous cardiovascular research, the majority of the cohorts used to
study cardiovascular risk are not racially or ethnically diverse (Goff et al., 2013). Racial and
ethnic populations have higher rates of cardiovascular disease and related risk factors (Ski, KingShier, & Thompson, 2013). The inclusion of racially and ethnically diverse samples in
cardiovascular research is warranted to address the high rate of cardiovascular disease.
The risk factors used to predict cardiovascular risk in the Framingham Risk score,
Reynolds Risk scores, and the Pooled Cohort Risk Score are strongly associated with
cardiovascular risk. Research incorporating novel risk factors of biological measurement, such as
carotid intima media thickness, peripheral arterial tonometry, and vasa vasorum, including their
potential role in cardiovascular research, has been endorsed by the American College of
Cardiology and American Heart Association (Go et al., 2014). However, in the present analysis,
these variables provided little to no independent predictive value. Thus, inclusion of the novel
risk factors of CIMT, PAT, and VV in cardiovascular research score stratification does not
appear to be warranted at this time, pending results from other studies that might attest to their
clinical, predictive value.
Study Strengths
The Heart SCORE dataset included a large array of demographic, clinical, and biological
measures collected on each participant. The study included a sample comprised of 43.8% black
participants (n=854) to allow comparative analyses by race. A lack of accurate cardiovascular
risk assessment in black individuals was addressed when developing the Pooled Cohort Risk
Equation. This study provided additional information for application of the Pooled Cohort Risk
Equations to the Heart SCORE population to assess the performance of this risk score in black
men and women. As recommended by the current American College of Cardiology and
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American Heart Association guidelines, this research included the Pooled Cohort Risk Equation
previously developed to assess the risk of stroke as a cardiovascular event/endpoint. Thus, the
present study appears to be unique in simultaneously evaluating three well-established
cardiovascular risk score algorithms using a common cardiovascular endpoint, and conducting
analyses by gender and race.
Study Limitations
Although this research study involved assessment of novel cardiovascular risk factors and
assessment of CVD risk in a diverse population, the study was subjected to several limitations.
The three cardiovascular risk scores were developed to predict different events/endpoints. The
events/endpoints of this study differed from those of which they were created to predict, and
thus, may have affected model performance. Additionally, when performing a secondary
analysis, the data used are limited by only those data collected in the primary research study.
This limitation became apparent when diabetic participants had to be excluded from analysis of
participants with the components for all three cardiovascular risk scores. Similarly, one risk
score required the Hemonglobin A1C values which were not collected in Heart SCORE.
Furthermore, diabetics comprised only 4.5% of the total sample used in these analyses. This was
a small representation of at risk population with a known need for cardiovascular risk
assessment.
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Appendix C: Heart SCORE Blood Pressure Data
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Appendix D: Heart SCORE Blood Pressure Medication
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Appendix E: Heart SCORE Glucose and Lipids
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Appendix J: Framingham Cardiovascular Risk Score
Table J1. Regression Coefficients and Hazard Ratios—Primary Model
Variable

a

Beta

p

Hazard
ratio

95% CI

Menb (10-year Baseline Survival: So(10) = 0.88936)
Log of age
Log of Total cholesterol
Log of HDL cholesterol
Log of SBP if not treated
Log of SBP if treated
Smoking
Diabetes

3.06117
1.12370
-0.93263
1.93303
1.99881
0.65451
0.57367

<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001

21.35
3.08
0.40
6.91
7.38
1.92
1.78

(14.03, 32.48)
(2.05, 4.62)
(0.30, 0.52)
(3.91, 12.20)
(4.22, 12.92)
(1.65, 2.24)
(1.43, 2.20)

Womenb (10-year Baseline Survival: So(10) = 0.95012)
Log of age
Log of Total cholesterol
Log of HDL cholesterol
Log of SBP if not treated
Log of SBP if treated
Smoking
Diabetes

2.32888
1.20904
-0.70833
2.76157
2.82263
0.52873
0.69154

<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001

b

10.27
3.35
0.49
15.82
16.82
1.70
2.00

(5.65, 18.64)
(2.00, 5.62)
(0.351, 0.691)
(7.86, 31.87)
(8.46, 33.46)
(1.40, 2.06)
(1.49, 2.67)

- 26.1931)
The 10-year risk for women can be calculated as 1-0.95012
where
- 23.9802)
X is the level for each risk factor; the risk for men is given as 1-0.88936

a

Estimated regression coefficient
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Appendix K: Reynolds Risk Scores
Reynolds Risk Score for Women
10B= 0.0799_age _ 3.137_natural logarithm (systolic blood pressure) _
0.180_natural logarithm (high-sensitivity C-reactive protein) _ 1.382_natural
-density lipoprotein
cholesterol) _ 0.134_hemoglobin A1c (%) (if diabetic) _ 0.818 (if current
smoker) _ 0.438 (if family history of premature myocardial infarction)
Reynolds Risk Score Men
10-year cardiovascular disease risk (%) = [1 – 0.8990 (exp[B-33.097])] x 100% where
B = 4.385 x natural logarithm(age) + 2.607 x natural logarithm(systolic blood pressure) + 0.963
x natural logarithm(total cholesterol) - 0.772 x natural logarithm(high-density lipoprotein
cholesterol) + 0.405 (if current smoker) + 0.102 x natural logarithm(high-sensitivity C-reactive
protein) + 0.541 (if parental history of premature myocardial infarction)
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Appendix L: Pooled Cohort Risk Equations
Table L1. Equation Parameters of the Pooled Cohort Equations for Estimation of 10-Year
Risk for Hard ASCVD* and Specific Examples for Each Race and Sex Group
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Table L1 (continued)

Note. Table retrieved May 5, 2014, from http://circ.ahajournals.org.

155

Figure L1. Estimating an individual’s 10-year risk for incident hard ASCVD.
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